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ABSTRACT 
 
  Heart failure is a chronic condition that increases the risk for death and 
disability.  Beta blockers and ACE inhibitors have become standard treatments in heart 
failure because clinical trials have demonstrated their beneficial effect on mortality and 
morbidity in these patients.    As not much is known about adherence to these 
medications, the main objectives of this project were to determine long term adherence 
to ACE inhibitors and beta blockers and determine how various degrees of adherence 
to a beta blocker can affect major health outcomes in patients with heart failure. 
 Data was obtained from Saskatchewan health from January 1, 1994 to 
December 31, 2003 for all heart failure patients from their first hospitalization for 
heart failure.  Adherence was calculated using the fill frequency measure of adherence, 
and all survival analyses were completed using the Cox proportional hazards model. 
 Although 14, 000 patients were admitted to hospital for a first admission for 
heart failure, only 1143 subjects started a beta blocker and 5084 subjects started an 
ACE inhibitor within 3 months of the index hospitalization.   Within the first year, 
adherence was excellent for both beta blockers (80.8 percent) and ACE inhibitors 
(82.5 percent).  The proportion of patients remaining adherent slowly decreased to 
reach approximately 60 percent, for both medication classes, after 4 years.  There was 
no significant difference in all-cause mortality between patients with high adherence 
and low adherence, but there appeared to be a trend towards decreased survival time in 
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those remaining adherent throughout the study period [HR = 1.18 (95% CI: 0.98 to 
1.43; p=0.07)]. 
 Since the overall rate of adherence to beta blockers was excellent in most 
patients during the first year, it is possible that non-adherence is not responsible for a 
significant burden of mortality in Saskatchewan heart failure patients, and perhaps and 
the focus of quality improvement should be optimal prescribing of evidence-based 
therapies, and continued adherence over time. 
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1.  INTRODUCTION 
1.1 Rationale 
 Heart failure is a progressive disease that is associated with a significantly 
shortened lifespan as well as debilitating symptoms that often require hospitalization. 1  
The average lifespan of a patient diagnosed with heart failure is approximately two 
years, and 50 percent will be hospitalized within the first year of diagnosis 2-4.  Recent 
reports estimate the prevalence to be between 1 and 7 percent, however, the number of 
afflicted individuals is expected to rise as the population ages. 4-8    
 Specific classes of medications are known to decrease the risk of 
hospitalization and death in heart failure patients. 1, 9, 10  Of these medications, certain 
beta blockers seem to have the most pronounced effect on decreasing mortality as 
demonstrated by several high quality randomized controlled trials.  However, not 
much is known about the success of these agents in a real world setting.  Currently, 
there is only one trial examining adherence rates to beta blockers, and one trial 
examining the effect of non-persistence to beta blockers on mortality rates.  
 
1.2 Purpose of the Study 
 The purpose of the study was to determine the real world adherence to beta 
blockers and ACE inhibitors in subjects after an initial hospital diagnosis of heart 
failure, and evaluate if poor adherence to beta blockers in these patients is associated 
with an increased risk for death or hospitalization in Saskatchewan.   
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1.3 Objectives 
The Primary Objectives of this study are as follows:   
 
A) Determine long term adherence to the major medications used in heart 
failure, namely ACE inhibitors and beta blockers. 
 
B)  Determine how various degrees of adherence to beta blockers can affect 
major health outcomes. 
 
The Secondary Objectives of this study are as follows:  
 
A)  Determine predictors of beta blocker adherence. 
 
B) Determine average doses of beta blockers used in heart failure in 
Saskatchewan. 
 
C) Examine trends in the initiation rates for beta blockers and ACE inhibitors 
in Saskatchewan over a 10 year period (1994 to 2004). 
 
1.4 Study Hypothesis 
 The majority of heart failure patients receiving beta blockers do not continue 
this therapy for the long term.  This lack of adherence negates the full mortality benefit 
that might accompany improved prescribing rates observed in recent years.   
 Heart failure patients who are non-adherent to beta blocker therapy will exhibit 
greater morbidity and mortality than adherent patients but less morbidity and mortality 
than those not prescribed this drug therapy.   
 
1.5 Significance of the Study 
 Despite the wealth of controlled clinical trials demonstrating benefits of heart 
failure medications, very little is known about the use of these drugs, especially beta-
blockers, in real world settings.  This study provides information about both 
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prescribing and subsequent adherence to heart failure medications that will reflect the 
extent to which clinical evidence has been translated into usual clinical practice in 
Saskatchewan.   Care-gaps identified by this study may direct action on the part of 
health care professionals to ensure that heart failure patients in the community are 
receiving the best possible medical care.       
 
1.6 Abbreviations 
ACE: angiotensin converting enzyme  
ARB: angiotensin receptor blocker 
RAAS: Renin-Angiotensin-Aldosterone System 
EF: ejection fraction 
OR: odds ratio 
 
1.7 Disclaimer 
This Study is based in part on de-identified data provided by the Saskatchewan 
Department of Health. The interpretation and conclusions contained herein do not 
necessarily represent those of the Government of Saskatchewan or the Saskatchewan 
Department of Health. 
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2. LITERATURE REVIEW 
2.1 Heart Failure  
 Heart failure is a progressive clinical syndrome resulting from a cardiac 
disorder that impairs the ability of the heart to pump blood throughout the circulatory 
system to meet the metabolic demands of the body. 1, 10-13  This impaired ability is due 
to a problem with ventricular relaxation and filling during diastole, ventricular 
contractile dysfunction during systole, or a combination of the two.  As such, heart 
failure is broken into two broad categories, systolic and diastolic heart failure. 1, 10-13  
Approximately twenty to fifty percent of incident cases of heart failure have preserved 
systolic function, 14, 15 but this may not be apparent in clinical practice if diagnostic 
testing is not performed.1, 10, 16  The demographics, prognosis, left ventricular structure 
and function between these two groups differ significantly. 17  Treatment of diastolic 
heart failure is similar to that of systolic heart failure, although this has not been firmly 
assessed by clinical trials. 1 
 The clinical syndrome of heart failure is characterized by signs and symptoms 
that can include fatigue, pulmonary and peripheral edema, bibasilar rales, pleural 
effusion, dyspnea, orthopnea, cough, wheezing, and decreased exercise tolerance. 1, 10, 
11, 18, 19  Based on a patient’s symptoms, their condition can be categorized into one of 
four functional classes developed by the New York Heart Association (NYHA).  
Patients in NYHA class I have symptoms of heart failure only at levels of exertion that 
would limit normal individuals.  As a patient’s class increases, so does their severity of 
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heart failure such that patients with NYHA class IV have symptoms at rest. 1, 11, 18  
Symptoms of heart failure decrease patient quality of life especially when compared to 
both the normal population and other disease groups in regards to physical, mental and 
social functioning.  Patients with heart failure report more severe physical impairment 
then patients with a history of arthritis or chronic lung disease. 20 
 Heart failure usually begins with some primary insult and a resultant change to 
the myocardium.  Major causes include coronary artery disease, hypertension, valve 
disease and dilated cardiomyopathy, of which genetics can play a role in up to thirty 
percent of patients. 1, 16, 19, 21  Control of risk factors that can damage the heart, such as 
hypertension, atherosclerotic disease and diabetes mellitus can help to prevent or delay 
the development of the disease. 1, 22  In fact, treatment of hypertension has shown a 
relative risk reduction of twenty-nine to over fifty percent. 23-26  Once developed, 
progression of heart failure is most influenced by activation of certain neurohormonal 
systems, such as the sympathetic nervous system and the renin-angiotensin-
aldosterone system.  These systems, which offer benefit to the failing heart in the short 
term, adversely affect myocardial function over time, resulting in increased 
hospitalization and death rates. 1, 10, 11, 15, 27 
 
2.2 Epidemiology of Heart Failure 
2.2.1 Incidence and Prevalence 
 Currently, the average age of heart failure patients at first presentation ranges 
from 73 to 80 years, with women being older when first diagnosed compared to men. 3, 
21, 28-30   The overall incidence of heart failure has been estimated to be between 4.2 
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and 14.4 per 1000 person-years, with the rates consistently higher among males in all 
age groups studied, 3, 5, 28-30  whereas, prevalence rates for heart failure range from 12 
to 70 per 1000 people, with prevalence being roughly equal between the sexes. 4-8  
Both incidence and prevalence increase dramatically with age such that 17 percent of 
the population over the age of 85 have heart failure. 3, 5-8, 21  With new therapies 
prolonging the life of heart failure patients, and the mean age of the population 
increasing, it is expected that the prevalence of heart failure will increase over time. 1, 2 
 
2.2.2 Hospitalization 
 The number of patients hospitalized with a principal diagnosis of heart failure 
has seen an increase of up to 53 percent over the last 2 decades for both men and 
women. 31, 32  Rates of hospitalization for heart failure also increase with age, such that 
at least 75% of patients hospitalized for heart failure are over the age of 65. 2, 31-33   
 In Canada, heart failure accounts for a total of 1.38 million hospital days over a 
one year period. 34  When heart failure was compared to other major disease states, it 
was shown to have the second highest total number of hospital days and the third 
highest number of patients affected. 34   Two-thirds of the cost of heart failure is due to 
hospitalizations, with health care utilization rising with increasing disease severity. 35  
The economic impact of heart failure is enormous in the developed world, accounting 
for 1-2% of global health care budgets. 35 
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2.2.3 Mortality 
 From the initial diagnosis of heart failure, epidemiological studies have shown 
that mean survival time is approximately 24 months. 3  Case-fatality rates appear to be 
highest during the first 3 months after diagnosis, with 4 to 11 percent of people dying 
within the first 30 days, 17 to 28 percent within 1 year, and 46 to 59 percent within 5 
years. 3, 29, 30  Fortunately, trends in death rates have shown a decrease over the last 50 
years with a decline of approximately 12 percent per decade. 29, 30  This improvement 
in survival can be attributed to new therapies for treating heart failure. 36 
 
2.3 Neurohormonal Activation in Heart Failure 
 The first step in the development of heart failure is usually some kind of initial 
injury to the myocardium that results in a prolonged decrease in both cardiac output 
and function. 1, 37  To counteract this decreased cardiac output, certain neurohormonal 
systems are activated, primarily the sympathetic nervous system and the renin-
angiotensin-aldosterone system (RAAS), which provide a transient maintenance of 
normal cardiac output. 37  Over time, constant activation of these systems cause 
progression of heart failure and increase the risk of hospitalization and death. 15, 19, 37, 38  
Cardiac remodeling also occurs, usually causing dilation of the ventricle, resulting in a 
more spherical shape to the heart.  This not only increases myocardial wall stress, but 
can cause mitral regurgitation, and increase the risk of arrhythmia. 15, 39 
 The adverse pathophysiologic effects of RAAS seen in heart failure are mostly 
driven by angiotensin II and aldosterone. 37, 38  Activation of the angiotensin-1 receptor 
by angiotensin II brings about vasoconstriction, and release of aldosterone, 
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catecholamines and vasopressin, leading to sodium and water retention, and increased 
sympathetic bombardment.  Angiotensin II can activate growth response genes leading 
to hypertrophy of the myocardium, and can also cause alterations in the collagen 
make-up of the heart. 37  Aldosterone increases sodium and water retention, and 
stimulates collagen production resulting in myocardial fibrosis.  Aldosterone also 
increases potassium and magnesium excretion, and may prevent uptake of 
norepinephrine by the heart, thus promoting arrhythmia formation. 37 
 It has been shown that there is both an increased and sustained sympathetic 
stimulation of cardiac tissue in patients with heart failure.  Although short term 
activation helps maintain cardiac performance, long term activation leads to many 
alterations in the beta adrenergic signal transduction system, one of which is down 
regulation of beta receptors.  37, 39-42 As a result of these and other changes that occur in 
the heart over time, routine contraction becomes suboptimal.  In addition to cardiac 
myocyte contractile dysfunction, chronic elevated sympathetic activity also leads to 
myocardial necrosis and induction of apoptosis. 39, 42  
 
2.4 Use of Drug Therapy in Heart Failure 
 In addition to diuretics, which regulate fluid volume and control symptoms, 
beta blockers, angiotensin converting enzyme inhibitors or angiotensin receptor 
blockers, and aldosterone antagonists have become the mainstay of drug therapy in 
heart failure.  These medications block the neurohormonal systems in the body most 
responsible for the progression and worsening of heart failure and can prolong the life 
 9
of many patients.  In addition, they have been shown to improve symptoms over time, 
and increase patient quality of life. 1, 9, 10   
 
2.4.1 Use of ACE Inhibitors in Heart Failure 
 ACE inhibitors have been part of the drug regimen of heart failure for the last 
two decades. 1  They work by inhibiting the ACE enzyme responsible for conversion 
of angiotensin I to angiotensin II, and also the breakdown of bradykinin, a vasodilatory 
hormone.  Through this action, ACE inhibitors cause vasodilation, and help to 
attenuate the rest of the RAA system. 37  Various ACE inhibitors have been studied in 
both chronic heart failure and in left ventricular dysfunction following a myocardial 
infarction.  They have not only been found to provide improvements in signs and 
symptoms of heart failure, but to decrease mortality and hospitalizations. 43-48  When 
used in heart failure, it is suggested that the benefits of ACE inhibitors are due to a 
class effect, and thus any one could be used. 49 
 Several randomized controlled trials have demonstrated the significant benefits 
of ACE inhibitors in patients with heart failure [Table 2.1]. 43-48  Three of the trials, 
CONSENSUS46, SOLVD43, and ATLAS45 examined patients with chronic heart 
failure whereas AIRE44, TRACE47, and SAVE48 were trials involving patients with left 
ventricular dysfunction following a myocardial infarction.  Seventy to eighty-two 
percent of all trial subjects were male with a mean age of approximately 65 years, and 
most patients were in class II or III heart failure, with the exception of CONSENSUS 
which included only class IV patients. 43, 45, 46   
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Table 2.1.  Summary of Landmark ACE Inhibitor Heart Failure Trials 43-48   
Trial CONSENSUS SOLVD ATLAS AIRE TRACE SAVE 
Sample Size      
(size in 
treatment) 
253 (127) 2569 (1285) 
3164 
(1568 HD**) 
(1596 LD**) 
1986 
(1004) 1749 (876) 
2231 
(1115) 
Description of 
Patients 
Chronic HF;  
NYHA IV 
Chronic 
HF; Mostly   
NYHA II-III 
Chronic HF; 
Mostly 
NYHA III 
Post-MI 
HF Post-MI HF 
Post-MI 
HF 
Drug Enalapril Enalapril Lisinopril Ramipril Trandolapril Captopril 
Mean Dose 
Achieved / 
day 
18.4mg 16.6mg 
HD – 
33.2mg 
LD – 4.5mg 
Not 
reported 
(10mg 
target) 
Not reported 
(4mg target) 
Not 
reported 
(150mg 
target) 
Mean/Median  
Follow-up 188 days 
41.4 
months 45.7 months 
15 
months Not reported 42 months 
Total 
Mortality (%)* 
39 vs 54 
RRR = 27% 
35 vs 40 
RRR = 
16% 
43 vs 45 
NS 
17 vs 23 
RRR = 
27% 
35 vs 42 
RRR = 22% 
20 vs 25 
RRR = 
19% 
CV Death (%)* 35 vs 51 RRR = 31% 
31 vs 36 
RRR = 
18% 
37 vs 40 
NS ----- 
26 vs 33 
RRR = 25% 
17 vs 21 
RRR = 
21% 
Sudden Death 
(%)* 
11 vs 11 
NS ----- ----- ----- 
12 vs 15 
RRR = 24% 
9 vs 11 
NS 
Admission to 
Hospital* ----- 
69 vs 74 
RRR = 7% RRR = 13% ----- ----- ----- 
HR = heart failure;  MI = myocardial infarction;  RRR = relative risk reduction;  CV = 
cardiovascular;  NS = not statistically significant 
* percentage of events in active treatment versus placebo   
** LD = low dose and HD = high dose.  There was no placebo control in this trial 
 
2.4.2 Use of Beta Blockers in Heart Failure 
 Beta blockers exert their beneficial effects by blocking the sympathetic nervous 
system at beta receptors. 1, 11, 39, 40, 42  Blocking these receptors in the heart reduces the 
negative impact norepinephrine has on cardiac remodeling and myocyte survival.  
Furthermore, in contrast to traditional concerns that beta blockers may be detrimental 
because they reduce heart rate and cardiac output, these agents actually can improve 
myocardial function by prolonging ventricular filling time, resulting in a more 
productive heartbeat. 50   
Three beta blockers have been extensively studied and have shown a decrease 
in morbidity and mortality in heart failure patients.  These beta blockers are metoprolol 
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and bisoprolol, which are beta-1 specific, and carvediolol, a non-specific beta blocker 
with alpha-1 blocking properties. 1, 11, 51-57  Atenolol, a beta-1 specific beta blocker has 
not been studied in heart failure, but is widely used for the condition, and is assumed 
to work due to properties similar to metoprolol and bisoprolol. 58   However, it is 
generally accepted that the benefits of beta blockers in heart failure are not a class 
effect and the use of proven drugs is recommended. 1, 9, 40, 59 
Table 2.2 gives a brief summary of major landmark trials of beta blockers used 
in heart failure and their major outcomes. 52-56, 59  For the most part, these trials 
included patients in NYHA class II and III, with the exception of COPERNICUS 54, 
which had class IV patients.  Three quarters of all study patients were male and the 
vast majority were white.  The mean age of patients in these trials was approximately 
62 years.  Total mortality was shown to be reduced by 23 to 65 percent. 51-56, 59  
 The main reason for using both beta blockers and ACE inhibitors in heart 
failure is their ability to reduce mortality and hospitalizations.  Prior to the introduction 
of beta blocker use in heart failure, the only medications proven to consistently reduce 
mortality were ACE inhibitors, which decreased death rates by approximately 23 
percent. 43-48, 60  In the beta blocker trials, significant mortality benefits were observed 
despite the fact that over 95 percent of patients were already taking an ACE inhibitor 
[Figure 2.1]. 51-56, 59  With the introduction of both these medications into the drug 
therapy regimen of heart failure patients, great strides have been made in reducing the 
death rate.  One year mortality can now approach 11.5 percent compared to 17 to 28 
percent seen prior to beta blocker use. 3, 29, 30, 52-56 
 
 12
Table 2.2.  Summary of Landmark Beta Blocker Heart Failure Trials 52-56 
Trial 
US 
Carvedilol 
HF Study 
MERIT-HF CIBIS-II COPERNICUS CAPRICORN 
Sample Size        
(size in 
treatment) 
1094 (696) 3991 (1990) 2647 (1327) 2289 (1156) 1959 (975) 
Drug Carvedilol Metoprolol CR/XL Bisoprolol Carvedilol Carvedilol 
Description of 
Patients** 
Mostly       
NYHA II-III; 
EF~23% 
Mostly        
NYHA II-III;    
EF~28% 
Mostly 
NYHA III; 
EF~27% 
NYHA IV;  
EF~20% 
Post-MI HF; 
EF~33% 
Mean Dose 
Achieved 45mg/day 159mg/day 
50% of pts 
reached 
target of 
10mg/d 
37mg/d 
74% of pts 
reached target 
of 50mg/d 
Mean/Median 
follow-up 6.5 months 12 months 16 months 10.4 months 12 months 
Total Mortality* 3.2 vs 7.8 RRR=65% 
7.2 vs 11 
RRR=34% 
12 vs 17 
RRR=34% 
11.2 vs 16.7 
RRR=35% 
12 vs 15 
RRR=23% 
CV Death* 2.9 vs 7.8  RRR=63% 
6.4 vs 10.1 
RRR=37% 
9 vs 12 
RRR=29% ---- 
11 vs 14 
RRR=25% 
Sudden Death* 1.7 vs 3.8 RRR=55% 
4.0 vs 6.6 
RRR=39% 
4 vs 6 
RRR=42% ---- 
5 vs 7 
RRR=26% 
Admission to 
Hospital* 
14.1 vs 19.6 
RRR=27% ----- 
33 vs 39 
RRR=20% ---- ---- 
CR/XL = controlled release formulation;  MI = myocardial infarction;  HF = heart 
failure;    EF = ejection fraction;  RRR = relative risk reduction;  CV = cardiovascular 
* percentage of events happening in active treatment versus placebo 
** EF = mean ejection fraction 
 
Figure 2.1.  One year mortality in ACE Inhibitor and Beta Blocker Trials 43, 44, 46-48, 52-56 
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2.4.3 Angiotensin Receptor Blockers (ARBs) 
 Angiotensin receptor blockers have been studied as alternative agents to ACE 
inhibitors and also as add-on therapy. 61-69  Like ACE inhibitors, angiotensin receptor 
blockers cause vasodilation, and help to attenuate the effects of angiotensin II, but 
instead of inhibiting the production of angiotensin II, ARBs block the angiotensin II 
receptor to inhibit its physiologic effects. 1  Since angiotensin II can be produced by 
other pathways besides the ACE enzyme, it had been postulated that ARBs may 
provide superior protection against its detrimental effects. 1, 61-63  However, ACE 
inhibitors also promote the accumulation of bradykinin which may be responsible for 
some clinically important benefits (as well as adverse effects such as cough) that are 
not observed with ARBs. 1, 37, 38      
 Of the ARBs that have been studied in heart failure patients, only valsartan and 
candesartan have shown significant benefits in mortality and hospitalization and are 
approved as acceptable agents. 61-66, 69  Overall, there is not enough evidence to 
conclude that these ARBs are completely equivalent to ACE inhibitors but they are 
good alternatives in patients who cannot tolerate an ACE inhibitor for various reasons. 
1  In addition, some benefit has been shown when an ARB is added to ACE inhibitor 
therapy, 63, 65 and this combination may be used in patients who are unable to tolerate a 
beta-blocker or who have continued symptoms while receiving ACE inhibitor and 
beta-blocker therapy. 1, 9   
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2.4.4 Aldosterone Antagonists 
 With the increased production of aldosterone in heart failure and its adverse 
effects on the heart, the RALES trial was completed to test the benefits of 
spironolactone, an aldosterone antagonist.  It was shown that in patients with NYHA 
class III and IV heart failure, the use of spironolactone in addition to usual heart failure 
medication decreased mortality by 30 percent. 70  Based on this trial, spironolactone is 
recommended in a select group of heart failure patients. 1, 12   
 
2.5 Adherence to Medications in Heart Failure 
 Despite the evidence showing a benefit for neurohormonal blockers in patients 
with heart failure, two barriers may stand in the way of optimal therapy: utilization and 
adherence.  For a medication to provide a benefit, it must first be prescribed to a 
patient with an indication for that drug.  In addition to being prescribed a medication 
for heart failure, a patient must fill the prescription and then continue to use it over the 
long term to retain its beneficial effects. 
 
2.5.1 Utilization of Heart Failure Medications 
 Guidelines recommend the routine use of ACE inhibitors or ARBs, and beta 
blockers in heart failure patients due to their proven benefits. 1, 10, 11, 27  However, 
recent studies indicate that these recommended medications are underused.  The major 
reason for underutilization of heart failure medications is assumed to be a result of 
physician under-prescribing.  However, other factors, such as unfilled discharge 
prescriptions, likely also play a role. 71   
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European, American and Canadian studies report that 28 to 75 percent of heart 
failure patients are prescribed an ACE inhibitor and only 11.8 to 41 percent are 
prescribed beta blockers. 58, 72-81  The prescribing rates for beta blockers are even lower 
in elderly patients 58, 77-79 and over half of all beta blocker prescriptions for heart 
failure are written by a cardiologist. 58, 79, 80  Prescription rates for combined use of beta 
blockers and ACE inhibitors is even lower at approximately 17 percent of the heart 
failure population, with one paper reporting 31 percent. 58, 72, 80  ARBs are considered a 
reasonable alternative to using an ACE inhibitor 1, 9, and combined utilization rates of 
either of these drug classes range from  61.7 to 82 percent. 36, 58, 72, 74, 77, 80 
 Since the publication of major landmark heart failure trials, utilization rates 
have been increasing.  In North America, ACE inhibitor utilization rates have 
remained relatively constant over the last 14 years, but the use of beta blockers has 
increased from approximately 5.9 percent in 1992 to 30 percent in 2001.  ARB 
utilization has also increased from approximately 0 percent in 1992 to 7 percent in 
2001. 36, 76, 81  Considering that most heart failure patients have an indication for both 
an ACE inhibitor and a beta blocker, these numbers although increasing, show a large 
gap in the optimal care of these patients. 
 In addition to prescribing rates, up-titration of these medications is an essential 
component of the optimal use of heart failure medications.  In clinical trials, up to 89 
percent of patients are able to maintain their beta blocker therapy, and about 70 percent 
of patients can maintain ACE inhibitor therapy once it is initiated and titrated to target 
doses. 43-48, 51, 52, 54, 55  In the real world, it has been shown that only 50 to 60 percent of 
patients reach target doses of these medications.  This may mean that many patients 
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are not receiving the maximum benefits seen in the large randomized controlled trials. 
58, 72, 77, 78, 80  Obviously, dosage level of many heart failure medications is a key 
component to evaluating the quality of care provided to these patients.  
 
2.5.2 Adherence to Drug Therapy 
 Adherence is usually defined as the degree to which patients are taking their 
drug therapy as prescribed by their physician, 82-84 but poor prescribing and lack of 
patient follow undoubtedly contributes to this problem.  Patient characteristics such as 
race, sex or socioeconomic status have not been consistently associated with 
adherence.  Instead, factors such as depression, cognitive impairment, poor 
relationships with the physician, or side effects of a medication have been cited as 
barriers to adherence. 82, 83  It is interesting to note that complexity of the drug therapy 
regimen in terms of multiple dosing and the use of multiple concomitant medications 
has frequently been cited as a major barrier to optimal adherence. 82, 83  
 There are various ways of measuring adherence, 82 including self-report via 
questionnaire or interview, 85, 86  pill counts, 87 electronic medication monitors, 88 
testing of serum drug levels, 89 and calculation through administrative databases. 47, 90-
94  Each method of measuring adherence has both advantages and disadvantages, but 
no method is considered to be the gold standard. 82, 95   
 Administrative databases use rates of refilling prescriptions in order to 
calculate adherence on a large number of subjects in an objective manner. 82, 95  
Although, there is no one perfect way of calculating adherence from these databases, it 
has been shown that taking the total days supply of a medication and dividing it by the 
 17
number of days of study participation is a reasonable way of calculating adherence. 95  
In the case, where days supply is not available, a fill frequency (or fills per month) 
measure of adherence has been used with comparable results. 96 
 
2.5.3 Adherence and Discontinuation Rates with Heart Failure Medications 
 Although adherence rates can vary depending on the type of measurement 
instrument used and the type of heart failure patient studied, various observational 
studies show adherence rates to be between 61 and 80 percent for all heart failure 
medications. 85, 97, 98  Evangelista and colleagues found self reported medication 
adherence rates of 96 percent in a heart failure clinic.  99  Although this report clearly 
highlights the success of a specific heart failure clinic, it is unlikely that adherence 
rates reach this level in the general heart failure population.    
 Monane et al. reported digoxin adherence in heart failure patients from the 
1980s. 100  It was found that the average patient had enough medication on hand to last 
for only two-thirds of a year.  Only 10 percent of patients had enough medication on 
hand to last them the whole 12 month follow up period. 100  
 Studies of ACE inhibitors show more promising rates of adherence.  ACE 
inhibitor adherence trials using both prescription databases and electronic monitoring 
have found the average adherence rate for ACE inhibitors range from 67 to 92.9 
percent. 88-91, 93, 94  Approximately 50 to 73 percent of these patients had adherence 
rates greater than 80 percent. 88-90, 93 
 There is currently only one trial examining adherence rates to beta blockers in 
heart failure.  Cole et al. examined adherence rates of ACE inhibitors and beta 
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blockers and the effect of drug copayment on these adherence rates using a database 
from a large, national health insurance plan in the United States. 91  Median adherence 
for beta blockers and ACE inhibitors was calculated to be 91.6 and 92.9 percent, 
respectively. 91    
 Other studies have examined beta blocker discontinuation rates. 81, 97, 101  In one 
study of a heart failure clinic where approximately 70 percent of patients were on beta 
blockers, maintenance of therapy was followed over a two year period through a 
retrospective chart review.  Of the patients prescribed beta blockers at the beginning of 
the trial, rates of continued therapy at 6, 12 and 24 months were 69, 70 and 74 percent.  
The most common reason for discontinuing the beta blocker was failure to reinitiate 
therapy after discharge from a hospitalization, which occurred in about 28 percent of 
patients.  Side effects and intolerance accounted for one-third of all discontinuations, 
and 40 percent of patients stopped the beta blocker for unknown reasons. There was no 
significant difference between the mean ages of patients in whom therapy was stopped 
compared to those who remained on beta blockers. 101  Again, this report summarizes 
an apparently successful heart failure clinic, however, the majority of heart failure 
patients in Saskatchewan do not have access to such a program.   
 A community based heart failure study examining trends in prescribing rates of 
beta blockers also reported on continuation of beta blocker use in patients. Heart 
failure patients who were started on a beta blocker were followed for ten years, and the 
average proportion of patients continuing with their therapy was 73 to 83 percent. 81  
However, adherence rates were not specifically examined over this period. 
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 A recent study examined the persistent use of evidenced based drug therapy in 
heart failure and included information on the use of beta blockers. 92  Gislason et al. 
analyzed over 100,000 patients discharged alive from their first hospitalization for 
heart failure using an administrative database.  Of all patients starting a beta blocker 
within three months of discharge, 69, 46 and 37 percent of patients had a break in 
therapy lasting at least 30, 90 and 180 days, respectively.  For breaks of 90 days or 
longer, approximately 50 percent of subjects reinitiated beta blocker treatment within 
one year, and of patients with a break of more than 180 days, only 27 percent 
reinitiated therapy. 
 Even if patients are prescribed ACE inhibitors and beta blockers, poor 
adherence or non-persistence with these medications play a role in causing 
decompensation and admission to hospital. 102-104  It is generally unknown whether 
poor adherence to these neurohormonal blockers can negatively affect mortality rates.  
Miura et al. studied the effects of non-adherence with digoxin and its effect on 
hospitalization and mortality in heart failure. 105  With a mean follow up of almost 6 
years, the number of hospitalizations was 2.5 times higher and risk of death was 
doubled in non-adherent patients. 105  Gislason et al studied non-persistence with heart 
failure medications and the effect this has on mortality. 92  Using a large population 
database to monitor frequency of prescription refill, it was found that patients who had 
a break in beta blocker therapy of at least 90 days had a 1.25 times higher risk of death 
(95% CI: 1.19 to 1.32; p<0.0001).  Patients with a break in ACE inhibitor or ARB 
therapy of at least 90 days had a 1.37 times higher risk of death (95% CI: 1.31 to 1.42; 
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p<0.0001).  Non-persistence with spironolactone did not result in a significant effect 
on mortality. 
 
2.5.4 Reasons for Non-adherence 
 There are numerous studies examining reasons for poor patient compliance 
with medications in both the general population and in heart failure patients.   
 Patients diagnosed with heart failure are inherently at risk of non-compliance 
due to a variety of factors, such as the presence of psychological or cognitive 
problems, medication related side effects, complexity of the medication regimen, 
patient’s lack of insight into their disease, cost of medications, concomitant diseases 
and inadequate follow-up from health care providers. 82, 83, 106, 107 
 When patients are asked about their reasons for not taking their prescribed 
medications, the most common answers are forgetfulness, other priorities preventing 
them from taking their medications, intentionally deciding to skip doses, lack of 
information about their prescribed medications, and certain emotional factors. 82 
 Over 70 percent of heart failure patients are prescribed three or more 
medications solely for heart failure, 58 and greater than 50 percent of patients have 
concurrent conditions that warrant other drug therapies. 51, 53, 108, 109  This often creates 
complex dosing regimens, resulting in decreased adherence rates. 82  Also, considering 
the average age of patients with heart failure is over 75, and steadily increasing, the 
presence of other concomitant diseases is also increasing, potentially decreasing the 
odds of compliance by about one third. 107, 108 
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2.6 Summary 
 Heart failure is a debilitating disease resulting in frequent hospitalizations and 
an increased risk of death.  The prescribing of life-prolonging therapy, such as ACE 
inhibitors and beta blockers in heart failure patients, along with their continued regular 
use should provide substantial benefit to these patients. 1, 9, 10  Considering the superior 
survival advantage observed with beta blocker use in clinical trials, non-adherence to 
these agents likely results in a significant excess of preventable deaths each year.  
Although reasonable success has been achieved in promoting greater prescribing of 
these agents in heart failure patients, it is unknown how many patients actually 
continue therapy long enough to achieve the benefits.  Currently, there is minimal data 
in terms of adherence rates to beta blockers and the effects that adherence can have on 
health outcomes. 
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3. STUDY DESIGN 
 A population based retrospective cohort study was created using linked 
administrative databases from the province of Saskatchewan, Canada.     
 Ethical approval was obtained from the University of Saskatchewan 
Biomedical Research Ethics Board on August 18, 2006 (ethics number 06-173 - 
Appendix A). 
 
3.1 Data Source 110   
 Saskatchewan has a publicly funded health system where residents of the 
province enjoy universal health insurance.   As a result, the Saskatchewan Department 
of Health (Sask Health) has accumulated a large amount of medical information over 
many years in electronic databases.  The databases include a population registry, 
prescription drug database, hospital services database, medical services database and 
vital statistics database, among others.  All data used in this study were obtained from 
Sask Health.  To ensure confidentiality throughout this study, all data were de-
identified by Saskatchewan Health personnel.  Person-level analysis was possible 
because Sask Health assigned eligible study subjects a study-specific unique identifier 
that only pertains to the present study and does not appear in any source database. 
 From the population registry, information is available on all residents eligible 
for Saskatchewan Health benefits.  This includes over 99 percent of the population, 
with the only exceptions being members of the Royal Canadian Mounted Police 
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(RCMP), members of the Canadian Forces, and federal penitentiary inmates.  It 
contains basic information about Saskatchewan beneficiaries such as coverage details, 
age, sex, place of residence and marital status.  For the current study, we were 
provided with the variables sex, year of birth and certain coverage details. 
  The prescription drug database includes information about prescription claims 
submitted by Saskatchewan pharmacies when that drug is on the Saskatchewan 
Formulary.  Approximately 91 percent of Saskatchewan Health beneficiaries are 
eligible for coverage through the Saskatchewan Drug Plan.  Exceptions include 
registered Indians, and veterans covered under veterans affairs.  For each eligible 
prescription dispensed, the following information was provided:  date of fill, the dose 
of the medication, the number of units dispensed, the dosage form, and an indicator of 
the type of special support received (if any) on drug costs. 
 The hospital services database captures information about all hospital visits for 
Saskatchewan beneficiaries (i.e., includes out-of-province hospitalizations).  
Information provided for every hospitalization included: the dates of admission and 
discharge, up to 25 diagnoses from each individual hospital visit, up to 20 procedures 
performed during the hospital stay, and the attending physician specialty of each 
hospital visit.   
 The medical services database captures data from physician service claims.    
The information provided included the date of physician visit, one diagnosis for that 
visit, and the specialty of physician seen.   
 The vital statistics database captures information on all births and deaths 
throughout Saskatchewan regardless of health coverage.  For every death that occurs in 
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Saskatchewan, information is obtained on the date of death, and the cause of death as 
recorded on the Medical Certificate of Death form.  This information can then be used 
to examine various reasons for death, and apply them as outcomes for analysis. 
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4. THE STUDY POPULATION 
 Subjects included all residents holding a valid Saskatchewan health card that 
were discharged from hospital alive with a first-ever primary or most-responsible 
diagnosis of heart failure between the dates of January 1, 1994 and December 31, 2003 
and were eligible for prescription drug benefits.  Additionally, each subject had to have 
a minimum of 5 years of continuous coverage prior to the index hospitalization to 
adequately assess their past history. 
 Any subject exhibiting the following within five years prior to the index 
hospitalization were excluded from the study:  hospitalization for heart failure or 
evidence of medical conditions that may have substantially decreased their life 
expectancy such as HIV/AIDS, solid organ transplant or terminal illness.  Evidence of 
these medical conditions was determined using the hospital services database, 
physician services database and the drug database (Appendix B). 
  
Patient Follow Up 
 Information on each eligible subject was collected from the date of discharge 
for the index hospitalization until the occurrence of one of the following:  
a)  Death, 
b)  Coverage termination (e.g., movement out of the province of Saskatchewan) 
c)  Organ transplantation or initiation of anti-rejection medication,  
d)  Diagnosis of HIV/AIDS or initiation of anti-retroviral therapy,  
e)  The end date of the study, Dec 31, 2003. 
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5. METHODOLOGY 
 Analyses of the study population were carried out in three separate phases 
using SPSS version 14.0 for Windows: 
 
Phase 1 Utilization of heart failure medications:  
i) Prescribing rates after discharge from index hospitalization, and  
ii) Average doses of beta blockers dispensed throughout the study period.   
 
Phase 2 Adherence:  
i) Adherence rates of beta blockers and ACE inhibitors, and 
ii) Predictors of beta blocker adherence. 
 
Phase 3 Survival analysis:  
i) Association between beta-blocker use/adherence and health related outcomes.  
 
5.1 Phase I: Utilization of Heart Failure Medications 
 The proportion of subjects filling at least one prescription for a guideline 
recommended heart failure medication (specifically beta blockers and ACE 
inhibitors/ARBs) within 30 days of discharge from the index hospitalization was 
calculated in two year intervals starting on January 1, 1994.  As such, all subjects were 
analyzed within a single time interval based on their year of entry into the study.   
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  For the calculation of beta-blocker utilization, only prescriptions for atenolol, 
metoprolol, bisoprolol or carvedilol were considered eligible.  In contrast, all available 
ACE inhibitors or ARBs on the market at the time of the study were used to determine 
utilization rates for these drug classes.   
 
5.1.1 Mean Daily Dose of Beta Blockers 
 All prescriptions for atenolol, bisoprolol, metoprolol and carvedilol were 
selected, and each drug was analyzed separately.  First, it was necessary to identify all 
prescription fills being dispensed on a monthly basis, because the prescription drug 
database in Saskatchewan does not capture a “days supply” variable.  Therefore, only 
subjects with fill quantities that were sensibly divisible by 34 days were selected on 
the assumption that a monthly prescription is intended to last 34 days.  This 
assumption is based on the contract between Sask Health and each Saskatchewan 
pharmacy that allows pharmacists to claim one dispensing fee for each 34-day supply 
dispensed (with some exceptions).  For example, a fill quantity of 68 is divisible by 34 
and would reflect a patient taking two tablets per day for one month.  Only beta 
blocker prescriptions with a fill quantity between 14 and 18, 28 and 35, or 56 and 70 
days were used to determine average daily doses.   
 For each one-month prescription selected, the quantity of tablets dispensed was 
divided by 34 in order to calculate the number of tablets/capsules taken per day 
between each fill.  To calculate the individual dose of beta blocker taken per day, the 
strength of the beta blocker dispensed at each fill was multiplied by the number of 
tablets per day.  This daily dose of beta blocker for all patients was then summed and 
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this number was divided by the total number of beta blocker fills to calculate the 
average dose of beta blocker per day.   
 
5.2 Phase II: Adherence to ACE inhibitors and Beta Blockers  
 All subjects filling a prescription for a beta blocker or ACE inhibitor at least 3 
times throughout the study period (January 1, 1994 to December 31, 2003) were 
included in this analysis, providing that the first prescription fill was within three 
months of discharge from the index hospitalization.  Adherence was calculated 
separately for beta blockers and ACE inhibitors.  Although any ACE inhibitor could be 
included for analysis, only the beta blockers atenolol, metoprolol, bisoprolol and 
carvedilol were selected.  Adherence rates were calculated at yearly intervals from the 
time of first fill, and eligible subjects had to have available data throughout the entire 
interval. 
 
Data Analysis 
 Adherence rates were calculated for each subject by taking the total number of 
fills in a given time period divided by the total number of months in that time period.  
This adherence measure is called the “fill frequency” and has been used in previous 
studies using Saskatchewan prescription drug data. 111  As a one month prescription fill 
under the Saskatchewan drug plan is for 34 days, to calculate the total number of 
months in a time period, the number of days in that period was divided by 34.  For 
example, the number of months in one year is calculated to be 10.74.   
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 Because this patient population requires frequent hospitalizations and in-
hospital prescription use is not captured in the database, all hospitalized days during 
the course of the observation period were accounted for in the adherence calculation.  
Specifically, the number of days that each subject spent in hospital was calculated and 
subtracted from the overall time in that interval.  The fill frequency measure was then 
calculated using the adjusted time interval.  In this way, adherence is adjusted for time 
spent in hospital on the assumption that subjects received study medications regularly 
during each hospital stay.     
 Once the fill frequency was calculated for each subject, the percentage of 
subjects exhibiting high adherence was then determined for each year.  High adherence 
was defined as having a fill frequency that is greater than or equal to 0.8 (or 80%). 
 Adherence to beta blockers was also calculated from a more global perspective 
incorporating subjects who filled their first prescription later than three months after 
discharge.  As such, the global adherence perspective takes into account how long it 
took for a subject to begin a beta blocker as well as whether or not they continued to 
take it on a regular basis.  To calculate adherence from this perspective the same steps 
were taken with one exception.  Instead of calculating adherence on a yearly basis 
from the time of first fill of a beta blocker, adherence was determined from the day a 
subject was discharged at their index hospitalization. 
 
Comparison of Adherence Measures 
 In an attempt to validate our fill frequency adherence measure, an alternate 
measure of adherence termed the tablets per day measure was also used to calculate 
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adherence for subjects taking beta blockers and ACE inhibitors, and these two 
measures were compared.   
 Tablets per day was calculated by adding all tablets that a subject had filled 
throughout a given time period and dividing this by the total number of days in that 
time period.  When performing this calculation one must take into account the fact that 
some subjects take a medication more than once a day, or perhaps take half a tablet per 
day.  Unfortunately, the Saskatchewan prescription drug database does not capture 
days supply of a prescription fill.  Thus, to accurately compare fills per month and 
tablets per day, adherence was calculated for medications that are usually only 
prescribed once a day.  For ACE inhibitor adherence lisinopril, ramipril, trandolopril 
and perindopril were used.  For beta blocker adherence bisoprolol and atenolol were 
used.  Furthermore, to ensure greater accuracy of the tablets per day measure, only 
subjects who had filled prescriptions for 28 to 35 tablets at a time were selected. 
 For each subject, both adherence measures were calculated over a one year 
period, and a Pearson’s correlation coefficient (r) was calculated to compare these 
adherence rates. 
 
Predictors of Beta Blocker Adherence 
 Adherence to beta blockers was calculated using the fill frequency measure of 
adherence from the time of discharge from index hospitalization until a subject’s exit 
from the study.  Subjects must have started a beta blocker within six months of the 
index hospitalization and survive longer than this period of time.  Once calculated, 
adherence was divided into two cohorts, 80 percent or greater and 50 percent or less, 
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which was meant to capture subjects that are strictly adherent, and strictly non-
adherent. 
 A binary logistic regression analysis was used to determine predictors of beta 
blocker adherence, with the dependent variable being beta blocker adherence. All 
available patient characteristics (see Appendix C for explanation of variables) were 
entered into one logistic regression model at the same time with the exception of  
chronic disease score, 112 Deyo comorbidity score, 113, 114 and number of diseases at 
index.  These three characteristics are all predictors of overall general health at 
baseline and it was felt that co-linearity would be present if they were all inserted 
within the model.  Each of the three characteristics was entered into the model in a 
stepwise fashion and the variable producing the lowest -2 log likelihood was used.  
Based on this, the number of diseases at index was used to adjust for overall general 
health at baseline in the logistic regression model.  
 
5.3 Phase III: Effects of Beta Blockers on Health Related Outcomes 
 To determine if an association exists between adherence to beta blockers 
(atenolol, metoprolol, bisoprolol and carvedilol) and major health outcomes, Cox 
proportional hazards models were constructed.  Each of the analyses is described 
below in detail. 
 
5.3.1 Effects of Beta Blocker Use on All-cause Mortality  
The Study Population  
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 To determine if the use of a beta blocker in ‘real world’ heart failure patients 
prolonged survival, all study subjects surviving at least six months past the index 
hospitalization were eligible for inclusion in this analysis so that a reasonable period of 
exposure to beta blockers could be ensured.  Subjects were then split into two cohorts 
based on whether or not they had filled a prescription for a beta blocker throughout the 
study period.  For those taking a beta blocker, the first fill had to occur within six 
months of the index hospitalization in order for these patients to be included in the 
analysis.  Patients filling the first prescription later than six months were excluded to 
minimize the likelihood of survivor treatment selection bias that has been observed in 
other observational studies of this nature. 115, 116      
 
Data Analysis 
 Beta blocker use/adherence and its effect on health related outcomes was 
assessed using Cox proportional hazards models.  The final multivariate Cox model for 
each endpoint included the following variables that were deemed to be clinically 
significant: age, sex, prior ischemic heart disease, and a measure of over-all general 
health at baseline (one of: CDS, Deyo comorbidity score or number of diseases at 
baseline – selected based on the variable producing the lowest -2 log likelihood in the 
final model).  As well, other clinically important variables were included in each 
endpoint analysis, and will be discussed within each relevant endpoint section.  To find 
the optimal multivariate model in all subsequent analyses, certain steps were 
performed. 117 
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 Step 1.  As there were 30 patient variables available (Appendix C) for inclusion 
into each Cox proportional hazards model, a univariate analysis was run for all non-
clinically important variables to determine if a significant effect (p < 0.1) on survival 
time was present.  Thus, approximately 26 univariate models were constructed for 
each outcome of interest. 
 Step 2.  Significant variables identified on univariate analysis were included 
into a multivariate model along with the clinically important variables.  As such, each 
variable in the model was adjusted for by all other included variables.  Variables that 
became non-significant (p>0.05) in the multivariate model were deleted from the final 
analysis, and variables not in the model were re-inserted to check for a significant 
effect in the presence of the other variables.  There were approximately 10 multivariate 
models constructed during step two for each outcome to determine the most 
appropriate variables to be included in the final model.   
 Step 3.  Upon determining the best variables for the model, beta blocker 
use/adherence was inserted into the model and possible interactions between variables 
were examined.  Any significant interactions were added to the model, and this final 
model was then used for survival analysis.   
 For the Cox proportional hazards model analyzing the effect of beta blocker 
use on all-cause mortality, the cohort of patients not taking a beta blocker was used as 
the reference group.  Clinically important variables were deemed to be sex, age, CDS, 
nitrate use, ACE/ARB use and prior IHD.  All other patient variables (see Appendix C 
for explanation of variables) were analyzed in univariate models to determine 
significance (Table 5.1).  Interactions between age2 and nitrate use, and age2 and beta  
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 Table 5.1.  Variables Considered for Use in the Final Cox Proportional Hazards      
        Model for Beta Blocker use on All-Cause Mortality 
Variables Significant in 
Univariate Analysis 
Clinically 
Important 
Variables 
Variables added to the Final 
Model 
Warfarin use NDP-CCB use Sex BB use Age2 
Digoxin use Spironolactone use Age Sex CDS 
Prior ACE use Prior BB use CDS Prior IHD ACE/ARB use 
Statin use Prior statin use Nitrate use  Digoxin use NDP-CCP use
Renal Failure Thiazide diuretic use 
ACE/ARB 
use  Prior ACE use Prior stain 
Anti-arrhythmic use  Prior IHD  Renal Failure Warfarin use 
Use of DM medication   Statin use Nitrate use 
Other HTN medication use   Spironolactone use 
Year at index hospitalization   Anti-  arrhythmic use 
Number of hospitalizations in the 
1st 6 months  Use of DM medication 
Type of doctor seeing patient at 
index  Other HTN medication use 
Number of hospitalizations in 
year prior to index   
Days spent in hospital at index 
hospitalization 
Days spent in hospital at index 
hospitalization   
Type of doctor seeing patient 
at index 
  Number of hospitalizations in the 1st 6 months 
NDP-CCB = non-dihydropyridine calcium channel blocker;  ACE = angiotensin 
converting enzyme inhibitor;  BB = beta blocker;  DM = diabetes mellitus;  HTN = 
hypertension;  CDS = chronic disease score;  ARB = angiotensin receptor blocker;  
IHD = ischemic heart disease.  See Appendix C for a more detailed definition of each 
variable. 
 
blocker use were detected and inserted into the final model.  All variables were 
categorical in nature with the exception of age which was a continuous variable.  Of 
note, the continuous variable age was determined not to be a linear term in regards to 
survival time, and thus other options were explored to optimize the model.  Both age2 
and age as a categorical variable were assessed for fit, and as determined by the -2 log 
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likelihood, age2 fit the current model better than the categorical variable of age, and 
thus was used in the final model. 
 
5.3.2 The Effect of Beta Blocker Adherence on Health Related Outcomes  
The Study Population 
 As a follow up to the previous analysis evaluating the impact of beta blocker 
use as a dichotomous classification, the following analysis was intended to 
discriminate between various adherence rates among beta blocker users, and determine 
any effect this might have upon mortality and hospitalization.   
 Only those filling a prescription for a beta blocker within the study period were 
selected for this analysis.  Two criteria were imposed upon these subjects taking a beta 
blocker.  First, subjects had to fill a beta blocker prescription within six months of 
index hospitalization.  Second, subjects had to have survived at least six months from 
the index hospitalization.  
 
Data Analysis 
 Adherence was calculated using the fill frequency measure of adherence from 
the time of index hospitalization, until the end of follow-up (i.e., the global 
perspective).  From the calculated adherence measure, each subject was separated into 
three distinct cohorts as follows:  
1.  Subjects receiving a beta blocker and who were > 80 percent adherent 
throughout the study.  This group of subjects is referred to as the high 
adherence cohort. 
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2.  Subjects receiving a beta blocker and who were between 50 and 80 percent 
adherent throughout the study.  This group of subjects is referred to as the 
medium adherence cohort. 
 
 
3.  Subjects receiving a beta blocker and who were < 50 percent adherent 
throughout the study.  This group of subjects is referred to as the low 
adherence cohort. 
 
All Cause Mortality 
 Beta blocker adherence and its effect on all-cause mortality was analyzed using 
a Cox proportional hazards model, with the low adherence cohort used as the reference 
group.  Clinically important variables were deemed to be sex, age, CDS, ACE 
inhibitor/ARB adherence, anti-arrhythmic drug use, use of diabetic medication and 
prior IHD.  All other patient variables (see Appendix C for explanation of variables) 
were analyzed in univariate models to determine significance (Table 5.2).  An 
interaction between digoxin and prior ischemic heart disease was found and added to 
the model.  All variables were categorical in nature with the exception of age, which 
was a continuous variable.  When tested, age was a linear predictor of survival time, 
and thus was included in the model unaltered. 
 Several subgroups were analyzed separately to evaluate the consistency of the 
results from the all-cause mortality model: 
• Patient age groups, where the continuous variable age was separated into 
three categories:  < 70, 71 to 79, and > 80  
• ACE inhibitor or ARB use 
• Male or female sex  
• History of ischemic heart disease 
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• Number of conditions at baseline, which was separated into two categories:                           
< 3 conditions or >3 conditions 
• Patients filling a prescription for a diabetes medication 
• Patients with evidence of renal failure 
• Medical visits in first 6 months, which was separated into two categories:                               
< 20 visits or > 20 visits 
 
Table 5.2.  Variables Considered for Use in the Final Cox Proportional Hazards Model 
        for Beta Blocker Adherence on All-Cause Mortality 
Variables Significant in 
Univariate Analysis 
Clinically 
Important 
Variables 
Variables added to the Final 
Model 
Warfarin use Digoxin use Sex BB adherence Age 
Prior ACE use Statin use Age Sex CDS 
Loop diuretic 
use Renal Failure CDS Prior IHD 
ACE/ARB 
adherence 
Nitrate use  Prior IHD Digoxin use Renal Failure 
Number of physician visits in the 
1st 6 months 
ACE/ARB 
adherence  Warfarin use  Prior stain 
Days spent in hospital at index 
hospitalization 
Anti-
arrhythmic 
use 
Statin use 
Anti-
arrhythmic 
use 
Drug benefits category at index Use of DM medication Use of DM medication 
  Other HTN medication use 
  
Number of physician visits in 
the 1st 6 months 
   Days spent in hospital at index hospitalization 
ACE = angiotensin converting enzyme inhibitor;  BB = beta blocker;  DM = diabetes 
mellitus;  HTN = hypertension;  CDS = chronic disease score;  ARB = angiotensin 
receptor blocker;  IHD = ischemic heart disease. See Appendix C for a more detailed 
definition of each variable. 
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Cardiovascular Mortality and Time to First Hospitalization 
 The effects of beta blocker adherence on cardiovascular mortality and time to 
first hospitalization, both considered to be secondary endpoints, were analyzed using a 
Cox proportional hazards model.  In each of these analyses the low adherence cohort 
was used as the reference group.   
 For the analysis of cardiovascular death, clinically important variables were 
deemed to be sex, age, CDS, ACE inhibitor/ARB adherence, use of diabetic 
medication and prior IHD.  All other patient variables (see Appendix C for explanation 
of variables) were analyzed in univariate models to determine significance (Table 5.3).  
No interactions were noted.  All variables were categorical in nature with the 
exception of age, which was a continuous variable.  When tested, age was a linear 
predictor of survival time, and thus was included in the model unaltered. 
 
Table 5.3.  Variables Considered for Use in the Final Cox Proportional Hazards Model 
        for Beta Blocker Adherence on Cardiovascular Death 
Variables Significant in 
Univariate Analysis 
Clinically 
Important 
Variables 
Variables added to the Final 
Model 
Warfarin use Nitrate use Sex BB adherence Age 
Digoxin use Statin use Age Sex CDS 
Prior ACE use Loop diuretic use CDS Prior IHD 
ACE/ARB 
adherence 
Renal Failure  Prior IHD Digoxin use Statin use 
Drug benefits category at index Use of DM medication Renal Failure Warfarin use 
Number of hospitalizations in the 
1st 6 months 
ACE/ARB 
adherence Use of DM medication  
Days spent in hospital at index 
hospitalization 
 
Number of hospitalizations in 
the 1st 6 months 
ACE = angiotensin converting enzyme inhibitor;  BB = beta blocker;  DM = diabetes 
mellitus;  CDS = chronic disease score;  ARB = angiotensin receptor blocker;  IHD = 
ischemic heart disease. See Appendix C for more a detailed definition of each variable. 
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 For the endpoint of time to first hospitalization, adherence was recalculated 
from the time of index hospitalization until the date of admission of first 
hospitalization, and only subjects having a first hospitalization six months after the 
index hospitalization were included in the analysis.  This was to help ensure that there 
was adequate time for adherent and non-adherent subjects to be distinguished.  
Subjects were once again separated into three adherence cohorts (high, medium and 
low adherence) for the purpose of analysis.  Clinically important variables were 
deemed to be sex, age, CDS, prior ACE inhibitor use, prior statin use, prior beta 
blocker use, prior IHD, and number of physician visits in the first six months.  As 
adherence was re-calculated from index until time to first hospitalization, only patient 
variables (see Appendix C for explanation of variables) available at baseline or prior 
were assessed for significance with univariate analysis (Table 5.4).   An interaction 
between sex and prior ischemic heart disease was noted and entered into the model.  
All variables were categorical in nature with the exception of age, which was a 
continuous variable.  When tested, age was a linear predictor of survival time, and thus 
was included in the model unaltered. 
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Table 5.4.  Variables Considered for Use in the Final Cox Proportional Hazards Model 
        for Beta Blocker Adherence on Time to First Hospitalization 
Variables Significant in 
Univariate Analysis 
Clinically 
Important 
Variables 
Variables added to the Final 
Model 
Year at index hospitalization Sex BB adherence Age 
Drug benefits category at 
index Age Sex CDS 
Type of doctor seeing patient 
at index CDS Prior IHD Prior BB use  
  Prior ACE use Prior ACE use Prior stain 
  Prior statin use Number of physician visits in the 1st 6 months 
 Prior IHD    
 Prior BB use   
 
Number of 
physician visits in 
the 1st 6 months 
 
ACE = angiotensin converting enzyme inhibitor;  BB = beta blocker;  CDS = chronic 
disease score;  IHD = ischemic heart disease. See Appendix C for a more detailed 
definition of each variable. 
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6. RESULTS 
 Of all eligible subjects residing in Saskatchewan between January 1, 1994 and 
December 31, 2003, there were 14, 445 patients admitted to hospital for a first 
admission for heart failure meeting the inclusion and exclusion criteria.  This 
population had an average age of 78.5 years (range of 6 to 107) and 51.7 percent were 
male.  The mean survival time of all subjects was 2.4 years with a range of 0 days to 
10 years.  Approximately 24 percent of subjects did not survive 3 months past the 
index hospitalization, limiting the number of subjects in subsequent analyses. 
 
6.1 Phase I: Utilization of Heart Failure Medications 
 A total of 3324 subjects (23 percent) started a beta blocker and 9796 subjects 
(67.7 percent) started an ACE inhibitor at some time throughout the study period.  
Using a t-test it was determined that subjects taking a beta blocker were significantly 
younger than those not on one (75 versus 80 years of age), as were subjects taking an 
ACE inhibitor or ARB (77 versus 80 years of age).  In addition, initiation of these 
medications was associated with more frequent physician visits within the first 6 
months. 
 Only 1572 subjects (12 percent) started a beta blocker within 30 days of 
discharge from the index hospitalization and are included in the analysis for utilization 
rates.  Although the overall utilization rate appears quite low, beta blocker prescribing  
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in this population has increased dramatically since 1994, reaching 25 percent in 
subjects discharged in the years 2002 and 2003 (Figure 6.1).     
 
 Figure 6.1.  Proportion of Subjects Filling at least One Prescription for a Beta Blocker 
         within 30 days of Discharge for Heart Failure  
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BB = beta blocker 
  
 Overall, there were 7111 subjects (57 percent) starting an ACE inhibitor or an 
ARB within 30 days of discharge from the index hospitalization.  When ACE inhibitor 
and ARB use is broken down into two year time intervals, there is little change over a 
10 year period, with utilization rates being between 51 to 60 percent (Figure 6.2) 
 
6.1.1 Mean Daily Dose of Beta Blockers 
 There were a total of 3324 subjects taking at least one of the four selected beta 
blockers at some time throughout the study period.  The average daily doses being 
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taken by study subjects receiving one-month prescriptions for atenolol, metoprolol, 
bisoprolol and carvedilol were calculated to be approximately 44mg, 59mg, 6mg, and 
18mg, respectively (Table 6.1).     
 
 Figure 6.2. Proportion of Subjects Filling at least One Prescription for an ACE or 
        ARB within 30 days of Discharge for Heart Failure 
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ACE = angiotensin converting enzyme inhibitor;  ARB = angiotensin receptor blocker 
 
Table 6.1. Mean Daily Doses of Beta Blockers used in Saskatchewan Patients 
Drug Mean Dose (mg/day) 
Range 
(mg/day) 
Number of 
Patients Taking 
Target Dose 
(mg/day) 
Atenolol 44.16 10.29 – 205.9 1362 Unknown 
Metoprolol 59.16 11.03 – 205.9 1470 100 to 200 
Bisoprolol 5.66 2.06 – 9.85 26 10 
Carvedilol 17.71 2.57 – 50.37 625 50 
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6.2 Phase II: Adherence to ACE inhibitors and Beta Blockers  
 There were 1143 subjects filling at least three prescriptions for a beta blocker 
and 5084 subjects filling at least three prescriptions for an ACE inhibitor within the 
first year.  As per the inclusion criteria described previously, all of these subjects 
initiated their respective medications within 3 months of the index hospitalization and 
survived for a minimum of 1 year.  As many of these patients did not survive (or were 
censored) for all subsequent years while calculating adherence, fewer patients were 
included in each adherence calculation at yearly intervals (Table 6.2).   
 
Table 6.2.  Number of Patients Included in Each Year for the Adherence Calculation 
Year Past 
Index 
Number of patients included 
in ACE inhibitor adherence 
Number of patients included 
in beta blocker adherence 
1 5084 1143 
2 3853 749 
3 2784 501 
4 1937 306 
 
 
 Adherence over the first year was excellent for both beta blockers (80.8 
percent) and ACE inhibitors (82.5 percent).  Thereafter, the proportion of patients 
remaining adherent slowly decreased to reach approximately 60 percent, for both 
medication classes, after 4 years (Figure 6.3). 
 This adherence analysis was also conducted on a broader population including 
subjects filling only one or two prescriptions over the observation period.  In this 
population, overall adherence to beta blockers and ACE inhibitors is attenuated by 
approximately 10 percent: 69.8 and 74.2 percent in the first year, 58.6 and 64.3 percent 
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in the second year, 53.2 and 61.4 percent in the third year and 50.7 and 56.9 percent in 
the fourth year, respectively.  
 
Figure 6.3.  Proportion of Patients Achieving 80% Adherence to ACE Inhibitors and 
        Beta Blockers in the Years Following Hospitalization 
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     ACE = angiotensin converting enzyme inhibitor;  BB = beta blocker 
 
 
 
 
 When examining the global adherence measure, which takes into account 
subjects who did not receive a beta blocker immediately after discharge, only 37.5 
percent of subjects are adherent to a beta blocker in the first year, and this decreases 
with time to 21 percent in year four (Figure 6.4).   
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Figure 6.4.  Proportion of Patients Achieving 80% Adherence to Beta Blockers when 
        Date of Discharge is used as the Beginning of the Observation Period 
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Comparison of Adherence Measures 
 The tablets per day and fill frequency adherence measures were calculated and 
compared for both beta blocker and ACE inhibitor subjects, with 158 and 1389 
subjects included in this calculation, respectively. These adherence measures were 
strongly correlated for both ACE inhibitors (r = 0.977) and beta blockers (r = 0.972) 
and were significant at the 0.01 level (Tables 6.3 and 6.4).   
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Table 6.3.  Correlation of Adherence Measures for ACE Inhibitors  
  Fill frequency Tabs per day 
Pearson Correlation 1 .977(**)
Sig. (2-tailed)  .000
Fill frequency 
N 1389 1389
Pearson Correlation .977(**) 1
Sig. (2-tailed) .000  
Tabs per day 
N 1389 1389
**  Correlation is significant at the 0.01 level (2-tailed). 
 
 
Table 6.4.  Correlation of Adherence Measures for Beta Blockers 
  Fill frequency Tabs per day 
Pearson Correlation 1 .972(**)
Sig. (2-tailed)  .000
Fill frequency 
N 158 158
Pearson Correlation .972(**) 1
Sig. (2-tailed) .000  
Tabs per day 
N 158 158
**  Correlation is significant at the 0.01 level (2-tailed). 
 
 
 
Predictors of Beta Blocker Adherence 
 There were 1815 subjects starting a beta blocker within 6 months of the index 
date who survived at least 6 months.  Of those, 1013 exhibited high adherence (>80 
percent) and 532 exhibited low adherence (< 50 percent).  From all of the variables 
entered into the logistic regression analysis, it appears that the greatest effect on 
predicting adherence is related to the time of index hospitalization.  For example, the 
odds of being adherent to a beta blocker are 5 times more likely in subjects having a 
first hospitalization in the years 2002 and 2003 compared to subjects entering the study 
in 1994. [OR = 5.0 (95% CI: 2.65 – 9.47; p<0.0001)].  Subjects who are adherent to 
ACE inhibitor or ARB medications are also more likely to be adherent to beta blockers 
[OR = 1.66 (95% CI: 1.12 – 2.46; p=0.011)].  Other significant predictors of adherence 
include female sex [OR = 1.35], use of diabetic medication [OR = 1.33], and filling the 
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beta blocker prescription within one month of the index hospitalization [OR = 1.5] 
(Table 6.5). 
 Conversely, if subjects are taking an antiarrhythmic medication [OR = 0.658 
(95% CI: 0.476 – 0.909; p=0.011)], a non-dihydropyridine calcium channel blocker 
[OR = 0.714 (95% CI: 0.511 – 0.996: p=0.047)], or have more than 34 visits to their 
physician in the first 6 months [OR = 0.522 (95% CI: 0.347 – 0.785; p = 0.002)], they 
have a greater likelihood of not being adherent to a beta blocker. 
 
Table 6.5. Positive Predictors of Overall Beta Blocker Adherence 
Characteristic Odds Ratio  p – Value 95% CI 
Patients adherent to an ACE 
inhibitor or ARB 1.66 0.011 1.12 – 2.46 
Female gender 1.35 0.019 1.05 – 1.73 
Beta blocker filled within 1 
month of index 1.50 0.007 1.10 – 1.99 
Use of diabetic medication 1.33 0.038 1.02 – 1.75 
    
Index in the years 94 and 95 1.00   
Index in the years 98 and 99 3.06 <0.0001 1.76 – 5.54 
Index in the years 00 and 01 3.20 <0.0001 1.74 – 5.86 
Index in the years 02 and 03 5.00 <0.0001 2.65 – 9.47 
CI = confidence interval;  ACE = angiotensin converting enzyme inhibitor;                           
ARB = angiotensin receptor blocker 
 
6.3 Phase III: Effects of Beta Blockers on Health Related Outcomes 
6.3.1 Effects of Beta Blocker Use on All-cause Mortality  
 A total of 9272 heart failure subjects were discharged alive and survived at 
least 6 months.  Of these subjects, 1815 used a beta blocker and 7457 never started one 
throughout the study period.  The average survival time for subjects on a beta blocker 
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was 2.76 years compared to subjects never taking a beta blocker who lived an average 
of 3.2 years.  An unadjusted hazard ratio for the effect of beta blocker use on mortality 
was calculated to be 0.671 (95% CI: 0.616 – 0.730; p<0.0001).  After controlling for 
several confounding factors, the use of a beta blocker was associated with a 61 percent 
reduction in the risk of death [HR = 0.39 (95% CI: 0.26 to 0.58; p<0.001)] when 
compared to patients not taking a beta blocker (Figure 6.5).   
 
Figure 6.5.  Adjusted Survival Curves of Beta Blocker Use using a Cox Proportional 
        Hazards Model 
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6.3.2 The Effect of Beta Blocker Adherence on Health Related Outcomes  
 Of the subgroup of beta blocker users described previously in the predictors of 
beta blocker adherence section (Phase II), an overall adherence rate of 74 percent was 
calculated from the time of index hospitalization until the end of follow up. 
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Approximately half of these subjects were male and the mean age was around 75, 
resembling the typical heart failure patients seen in epidemiological studies.  Patients 
in the high adherence group had higher chronic disease scores compared to the other 
two cohorts, however, the number of medical visits within the first six months is 
higher in the low adherence group (Table 6.6). 
 
Table 6.6. General Patient Characteristics of Patients using Beta Blockers 
Baseline Characteristics (%) 
High 
Adherence 
(n=1013) 
Medium 
Adherence 
(n=270) 
Low 
Adherence   
(n=532) 
Mean Follow-up* 2.5 yrs 2.6 yrs 3.2 yrs 
Male* 488 (48.2) 157 (58.1) 286 (53.8) 
Age [mean + SD] 74.9 [11] 73.9 [12] 75.1 [11] 
Numb days at index hosp       
[mean + SD] 7.5 [8.8] 6.6 [ 5.9] 7.7 [8.0] 
Medical visits in 1st 6 months*    
[mean + SD] 22.8 [16] 23.3 [17] 25.9 [18] 
    
Chronic Disease Score*    
          0 to 3 123 (12.1) 42 (15.6) 91 (17.1) 
          4 to 5 167 (16.5) 48 (17.8) 95 (17.9) 
          6 to 7 269 (26.6) 69 (25.6) 162 (30.5) 
          8 to 9 239 (23.6) 53 (19.6) 103 (19.4) 
          10 to 22 215 (21.2) 58 (21.5) 81 (15.2) 
SD = standard deviation 
* indicates a significant (p<0.05) difference between groups.  Significance was 
determined using a t-test for continuous variables and a chi-square analysis for 
categorical variables. 
 
 
 Prior ACE inhibitor, beta blocker and statin use, as well as prior ischemic heart 
disease is seen more frequently in the high adherence cohort compared to the other 
groups.  The majority of subjects in all three cohorts had less than three hospital 
admissions in the year prior to the index hospitalization (Table 6.7). 
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Table 6.7. Patient Characteristics Prior to Study Entry in Patients using Beta Blockers 
Baseline Characteristics (%) 
High 
Adherence 
(n=1013) 
Medium 
Adherence 
(n=270) 
Low 
Adherence 
(n=532) 
 Prior ACE inhibitor use* 534 (52.7) 146 (54.1) 227 (42.7) 
 Prior beta blocker use* 558 (55.1) 139 (51.5) 232 (43.6) 
 Prior statin use* 226 (22.3) 45 (16.7) 63 (11.8) 
 Prior IHD* 518 (51.1) 124 (45.9) 238 (44.7) 
    
Hospitalizations in year prior    
          0 470 (46.4) 122 (45.2) 252 (47.4) 
          1 to 2 389 (38.4) 104 (38.5) 206 (38.7) 
          3 to 18 154 (15.2) 44 (16.3) 74 (13.9) 
ACE = angiotensin converting enzyme;  IHD = ischemic heart disease 
* indicates a significant (p<0.05) difference between groups.  Significance was 
determined using a t-test for continuous variables and a chi-square analysis for 
categorical variables. 
 
 
 As to be expected in the heart failure population, over 90 percent of subjects 
taking a beta blocker also used a loop diuretic throughout the study period.  Also, over 
85 percent of subjects taking a beta blocker filled a prescription for an ACE inhibitor 
or an ARB.  Subjects in the low adherence cohort were less likely to be adherent to an 
ACE inhibitor or ARB compared to the high beta blocker adherence group.  Other 
medication use was similar between groups with the exception of lower digoxin use 
and higher statin use in patients exhibiting high adherence (Table 6.8).  Overall, there 
appeared to be few clinically important differences between the adherence cohorts.     
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Table 6.8. Patient Characteristics: Use of Heart Failure Medication Throughout the 
      Study Period in Patients using Beta Blockers 
Baseline Characteristics (%) 
High 
Adherence 
(n=1013) 
Medium 
Adherence 
(n=270) 
Low 
Adherence   
(n=532) 
 Loop diuretic use 947 (93.5) 252 (93.3) 499 (93.8) 
 ACE or ARB use     
       Not used 109 (10.8) 37 (13.7) 65 (12.2) 
       < 80% adherence* 214 (21.1) 94 (34.8) 217 (40.8) 
       > 80% adherence* 690 (68.1) 139 (51.5) 250 (47) 
 Spironolactone use* 436 (43) 133 (49.3) 206 (38.7) 
 Digoxin use* 449 (44.3) 134 (49.6) 290 (54.5) 
 Statin use* 371 (36.6) 89 (33) 124 (23.3) 
 Hydralazine use 59 (5.8) 18 (6.7) 28 (5.3) 
 Nitrate use  650 (64.2) 171 (63.3) 341 (64.1) 
ACE = angiotensin converting enzyme inhibitor;  ARB = angiotensin receptor blocker 
* indicates a significant (p<0.05) difference between groups.  Significance was 
determined using a t-test for continuous variables and a chi-square analysis for 
categorical variables. 
 
 
All-cause Mortality 
 Of the patients in the three adherence cohorts, 202 (38 percent) died in the low 
adherence, 96 (35.6 percent) died in the medium adherence, and 317 (31.3 percent) 
died in the high adherence cohort, and the median survival time for all patients dying 
within these cohorts was 2.2, 1.9 and 1.6 years, respectively.  Compared to those 
exhibiting low adherence, patients in the medium adherence cohort (50 to 80 percent) 
had significantly shorter survival [HR = 1.41 (95% CI: 1.09 to 1.81; p<0.01)].  
Although there was no significant difference in survival between the high and low 
adherence cohorts, there appeared to be a trend towards higher mortality in those who 
remained adherent [HR = 1.18 (95% CI: 0.98 to 1.43; p=0.07) (Figure 6.6 and Table 
6.9).   
 Similar findings were discovered when various subgroups were examined.  The 
low adherence cohort consistently demonstrated the longest survival time, and survival 
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curves were comparable to the results of all beta blocker users.  Any slight differences 
seen within the survival curves of the subgroups are deemed to be due to chance 
variation and small sample size. 
 
Figure 6.6. Adjusted Survival Curves for Beta Blocker Adherence with an Outcome of  
       All Cause Mortality using a Cox Proportional Hazards Model 
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< 50% = the low adherence cohort;  50 to 80% = the medium adherence cohort;           
> 80% = the high adherence cohort 
  
 
 
Cardiovascular Mortality and Time to First Hospitalization 
 There were a total of 375 cardiovascular deaths among the 1815 beta blocker 
subjects included in this analysis.  One hundred and thirty subjects (24.4 percent) died 
of a cardiovascular cause in the low adherence cohort, 61 (22.6 percent) in the medium 
adherence and 184 (18.2 percent) in the high adherence cohort.  Of those dying of a 
 54
cardiovascular cause in the low, medium and high adherence cohorts, the median 
survival time was 2.1, 1.8 and 1.7 years, respectively.   
 Compared to the low adherence group, the 50 to 80 percent cohort had a hazard 
ratio of 1.37 (95% CI: 1.01 to 1.87; p<0.045), thus indicating a significantly decreased 
survival time.  The > 80 percent adherence group, when compared to the low 
adherence cohort, had a HR of 1.1 (95% CI: 0.87 to 1.39; p=0.42).  (Figure 6.7 and 
Table 6.9).   
 
Figure 6.7. Adjusted Survival Curves for Beta Blocker Adherence with an Outcome of  
       Cardiovascular Mortality using a Cox Proportional Hazards Model 
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< 50% = the low adherence cohort;  50 to 80% = the medium adherence cohort;           
> 80% = the high adherence cohort 
 
 
 
 The sample size in the survival analysis for time to first hospitalization was 
drastically reduced compared to the analysis of all-cause mortality.  The reason for this 
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is that many of the patients who were initiated on a beta blocker throughout the study 
period did not start it prior to their first hospitalization, and also because the first 
hospitalization had to be at least 6 months after index.  Thus, only a total of 484 
patients were included in the analysis of this secondary endpoint.  There were 86 
patients in the low adherence, 82 patients in the medium adherence and 316 patients in 
the high adherence cohorts.   
 The average time until the first hospitalization was 17 months from the index 
date.  Approximately 50 percent of subjects were hospitalized within the first year of 
their index hospitalization, with 80 percent of subjects being hospitalized within 2 
years.   
 Compared to the low adherence group, the medium adherence cohort had a 
significantly greater risk for repeat hospitalization [HR = 1.44 (95% CI: 1.05 to 1.99; 
p=0.025)].  In the high adherence cohort, although not statistically significant, there 
appears to be a higher risk for hospitalization compared to the low adherence group 
[HR = 1.21 (95% CI: 0.94 to 1.55; p=0.15)] (Figure 6.8 and Table 6.9). 
 
 
Table 6.9.  Results of Survival Analyses 
 Hazard Ratio (95% Confidence Interval) 
 High vs Low 
Adherence Cohort 
Medium vs Low 
Adherence Cohort 
All-cause Mortality 1.18 (0.98 to 1.43) 1.41 (1.09 to 1.81) 
Cardiovascular Mortality 1.10 (0.87 to 1.39) 1.37 (1.01 to 1.87) 
Time to First Hospitalization 1.21 (0.94 to 1.55) 1.44 (1.05 to 1.99) 
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Figure 6.8.  Adjust Survival Curves for Beta Blocker Adherence with an Outcome of  
        Time to First Hospitalization using a Cox Proportional Hazards Model 
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< 50% = the low adherence cohort;  50 to 80% = the medium adherence cohort;           
> 80% = the high adherence cohort 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 57
 
 
 
 
 
7.  DISCUSSION 
 Between 1994 and 2003, over 14,000 subjects were discharged from a 
Saskatchewan hospital with a first-ever primary or most responsible diagnosis of heart 
failure.  In the Saskatchewan population, the average age of heart failure patients was 
78.5 years with 51.7 percent being male.  These characteristics are similar to subjects 
seen in other population based heart failure papers.  For example, patients with newly 
diagnosed heart failure have been reported to have a mean age ranging from 71.3 to 80 
years with approximately 53 percent of the patient population being male. 5, 21, 28, 58  de 
Giuli et al. reports an average survival time of heart failure patients to be 
approximately two years, which was similar to the Saskatchewan population (2.4 
years). 3   
  
7.1 Phase I: Utilization of Heart Failure Medications 
 Prior to the publication of landmark trials showing a mortality benefit in heart 
failure patients, use of beta blockers in Saskatchewan was minimal at 2.6 percent.  
After the benefit of beta blockers was recognized in 1996, their use almost doubled 
every two years and by the end of 2003, approximately 25 percent of heart failure 
patients were receiving a beta blocker (Figure 6.1 in Results section).  This increase in 
use over time in the Saskatchewan heart failure population is comparable to other 
Canadian provinces (Figure 7.1). 36, 76  Utilization of beta blockers in other countries is 
also similar, but slightly higher than that seen in Saskatchewan.  The EuroHeart 
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Failure Survey, which includes data from 24 countries belonging to the European 
Society of Cardiology, reported an average beta blocker utilization rate of 36.9 percent 
(range of 10 to 66 percent) in 2003. 58 
  
Figure 7.1.  Utilization of Beta Blockers within Canada36, 76       
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 Despite the rapidly increasing utilization rate, only 25 percent of patients at the 
end of 2003 started a beta blocker within 30 days of being discharged from their index 
hospitalization.  Although poor uptake of evidence-based guidelines likely plays a 
significant role, subtle diagnostic issues may also have contributed to the low rates of 
beta blocker use.  For example, diastolic heart failure may account for 50 percent or 
more of all heart failure admissions and although beta blockers may provide some 
benefit, they are not specifically targeted in this group of patients because few clinical 
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trials are available to guide drug therapy. 1, 9  Using data from Saskatchewan Health 
databases, it was impossible to distinguish between patients exhibiting heart failure 
with preserved systolic function (diastolic heart failure) versus those with systolic 
dysfunction.  In addition, it is plausible that certain patients were misdiagnosed with 
heart failure and did not require a beta blocker after discharge.  However, researchers 
in Ontario have demonstrated their administrative heart failure diagnoses to be very 
accurate, at least in hospitals with frequent heart failure admissions. 118    
  It has been reported that only 15 percent of heart failure patients have a 
contraindication for beta blocker use. 119  If this is the case, the current use of beta 
blockers in Saskatchewan, even taking into account the prevalence of diastolic heart 
failure, indicates a vast underutilization of that drug class in heart failure patients, and 
the benefits seen in randomized controlled trials are not being realized in the general 
heart failure population. 
 In contrast to the increasing use of beta blockers, utilization of ACE inhibitors 
and ARBs within a 10 year period has remained relatively unchanged in Saskatchewan 
at approximately 60 percent (Figure 6.2 in Results section).  Since landmark ACE 
inhibitor trials were first published in the late 1980s and early 1990s, it is likely that a 
trend for increased prescribing was observed prior to our observation period (1994-
2003).   This appears to be true, as one study in the United States showed an increase 
in ACE inhibitor use from 24 percent in 1990 to 34 percent in 1992, and then a plateau 
with a very gradual increase to 38 percent in 2002. 73  Studies within the last seven 
years have shown similar utilization rates for ACE inhibitors (range of 40 to 85 
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percent) that were seen in the Saskatchewan population, with utilization rates of ARBs 
being less than 10 percent. 58, 72, 75-77, 80   
 It is recommended that all heart failure patients with systolic dysfunction 
receive an ACE inhibitor, and ACE inhibitors should also be considered for most 
patients with preserved systolic function. 9  Only 6.7 to 17 percent of patients were 
unable to tolerate an ACE inhibitor in clinical trials. 44-46, 61  Although poor tolerance 
may be slightly higher in a community based heart failure population, utilization of 
these important classes of medication would also seem to be problematic in 
Saskatchewan. 
 
7.1.1 Mean Daily Dose of Beta Blockers 
 Beta blockers prescribed for heart failure patients in Saskatchewan fail to meet 
target doses by one third to a half.  Although, a target dose for atenolol has not been 
established, it is probable that atenolol would have a target dose of 100mg per day 
based on its use in other cardiovascular conditions.  Of the subjects taking atenolol, 
there were only 41 (3 percent) with an average daily dose of 100 mg or higher.  
Metoprolol succinate, which was used in the MERIT-HF 52 trial at a target dose of 200 
mg a day, is not available for use in Canada.  A target dose for metoprolol tartrate 
(available in Canada) has not been formally established, however, this formulation was 
titrated to a target of 100 mg a day in the COMET 51 trial.  In the Saskatchewan 
population, only 157 subjects (10.7 percent) taking metoprolol had an average dose of 
100 mg or higher, with only 18 (1 percent) having a mean daily dose of 200 mg or 
higher.   A target dose of 25 mg twice daily for carvedilol in chronic heart failure 
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patients was seen in the COPERNICUS and COMET trial, along with the US 
Carvedilol Heart Failure Study. 51, 55, 120  In Saskatchewan, there were only 11 subjects 
(1.8 percent) taking an average daily dose of carvedilol reaching 50 mg or more per 
day.   
 Heart failure guidelines suggest that beta blocker doses should be titrated to 
target levels in all patients if tolerated. 1, 9  Despite this suggestion, it appears that 
many patients do not have their doses increased.  Interestingly, this problem appears to 
be prevalent around the world.  The EuroHeart Failure survey showed average daily 
doses that were very similar to the results shown in Saskatchewan (46, 75, 4.7 and 17.6 
mg per day (EuroHeart) versus 44, 59, 5.6, and 18mg per day (Saskatchewan) for 
atenolol, metoprolol, bisoprolol and carvedilol, respectively). 58  Various other 
population based studies reveal similar results, with prescribed beta blocker doses only 
reaching up to 50 percent of target. 72, 75, 80, 92  Thus, not only is there a vast 
underutilization of beta blockers in heart failure, but it appears that target doses are not 
met in the majority of patients. 
 Reasons for the low doses seen may include the advanced age of heart failure 
patients, the inability for a patient to tolerate higher doses due to the severity of the 
disease, lack of knowledge in regards to heart failure guidelines and/or clinical inertia.  
Regardless of the reason, it is generally felt that titrating beta blockers to target doses 
will provide greater benefits.  Post-hoc analysis of the CIBIS-II and MERIT-HF trials 
show that there may be a greater benefit for target doses of beta blockers compared to 
low doses, but when compared to placebo, both dosage levels had relatively the same 
benefit on mortality. 121, 122  The MOCHA trial showed that the use of carvedilol at 25 
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mg twice daily resulted in a mortality of 1.1 percent compared to doses of 12.5 mg or 
6.25 mg twice daily, which resulted in a mortality of approximately 6 percent. 123  
Unfortunately, this trial was not designed to evaluate the effect of dose on mortality 
and the number of deaths was small.  In a post-hoc analysis of the SENIORS trial, 
target and medium doses of nebivolol, a beta-1 specific beta blocker with vasodilating 
properties (not available in Canada), provided greater benefit in terms of all cause 
mortality or cardiovascular hospitalization then low dose nebivolol when compared to 
placebo. 124  Although results are conflicting, all of these post-hoc analyses agree that 
the use of a beta blocker in systolic heart failure patients at any dose will provide some 
benefit, but that target doses should be strived for if tolerated. 
 
7.2 Phase II: Adherence to ACE inhibitors and Beta Blockers  
 Unlike most trials of adherence to medication in heart failure, it was the goal of 
this study to calculate adherence on a yearly basis and observe trends over a four year 
period.  It appears that the majority of heart failure patients in Saskatchewan are 
adherent with both beta blocker and ACE inhibitor therapy, especially in the first year, 
as adherence rates reach approximately 80 percent.  Unfortunately a decrease in 
adherence is seen over time, such that approximately only 60 percent of patients are 
adherent after four years (Figure 6.3 in the Results section).  Furthermore, a significant 
number of individuals stop these life-saving medications after only one or two fills.  It 
is interesting to note that both ACE inhibitor and beta blocker adherence in the 
Saskatchewan population is almost identical and that this similarity continues over 
time. 
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 When the adherence measure is calculated from the day of discharge rather 
than the first prescription fill, only one third of all patients meet the 80 percent 
requirement for optimal adherence.  Subsequently, less than one-quarter are adherent 
after four years (Figure 6.4 in the Results section).  This adherence perspective 
suggests that many of the patients requiring a beta blocker (evidenced by beta blocker 
use at some point in time), do not receive this life-saving medication early on in their 
disease.  This is unfortunate, as the benefits of beta blockers have been observed in 
heart failure patients from the time of diagnosis, and guidelines suggest starting a beta 
blocker as early as possible after diagnosis of left ventricular dysfunction. 1, 9, 44, 53  
 Regardless of the perspective examined, a decrease in adherence is still 
observed over time.  Diminishing adherence rates may be a result of problems with 
memory, concerns over medication cost, lack of understanding of the benefits of the 
medication or various other reasons.  Perhaps heart failure patients are not reminded of 
these benefits often enough and have no incentive to continue taking them over the 
long term.   
In contrast to patient-specific issues, it is also possible that physicians are 
discontinuing the use of these medications for various reasons.  A study examining 
persistence with medication in heart failure patients reported that a common reason for 
discontinuation with a beta blocker was failure to re-initiate therapy after a hospital 
admission. 101  Whatever the reason, it is the responsibility of health care professionals 
to ensure that patients with heart failure are prescribed life-saving medications on an 
ongoing basis and that they strive to minimize the barriers associated with chronic 
medication adherence.    
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 Despite the numerous studies examining medication adherence in general, it is 
unknown which method of measuring adherence is the most appropriate.  Using 
Saskatchewan Health data, it was possible to evaluate a large number of subjects who 
were unaware that adherence was being examined.  As such, their refill habits were 
likely to be “natural”.  Furthermore, it has been shown that there is a high correlation 
between adherence calculated from a prescription claims database and adherence from 
pill counts. 87  None of the previously published adherence papers in heart failure 
calculated adherence using the global perspective, and thus do not take into account 
the time to initiation of heart failure medication from diagnosis. 
 Our study supports previous findings, showing that adherence to medications in 
heart failure is relatively high and usually exceeds 70 percent, with many studies 
reporting adherence rates of over 80 or 90 percent. 84-86, 88-90, 93, 94, 100  van der Wal et al. 
reported overall medication adherence in heart failure patients to be 98.6 percent. 125  
However, this study used a questionnaire on hospitalized patients asking about 
adherence over the past week, the past month and three months prior to hospitalization, 
relying on patient memory and self-report. 125  In contrast, the results generated from 
our present study were based on a more objective measure of adherence.   
 Adherence to ACE inhibitors has been reported to range from 67 to 92.9 
percent, which is similar to rates reported herein.88-91, 93, 94  Sample sizes varied from 
64 to 5259 subjects, and adherence was measured using administrative databases, 
pharmacy records, and electronic counters (MEMS).  Consecutive changes in 
adherence on a yearly basis had not been examined in any of the previously published 
ACE inhibitor adherence papers.  
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 Aside from papers examining discontinuation rates or persistence of use, only 
one study measuring adherence to beta blockers could be found. 91  Cole et al. used a 
large database from the UnitedHealthcare insurance plan to measure adherence to both 
beta blockers and ACE inhibitors and examine the effect that various copayment prices 
have on this adherence rate.  Just over 5000 subjects taking a beta blocker were 
included in the adherence calculation and the median adherence rate was 91.6 percent.  
As all subjects in this trial had coverage under the UnitedHealthcare insurance plan, 
subjects were not paying full price for heart failure medications, and this may have 
resulted in a higher than expected median adherence rate.  Also of note, subjects with 
adherence below 20 percent and over 120 percent were excluded.  The results of the 
study by Cole et al. reflect excellent adherence rates for beta blockers that are higher 
than, but similar to, rates seen in the Saskatchewan population.   
 
Predictors of Beta Blocker Adherence 
 In terms of predicting adherence to beta blockers in the Saskatchewan 
population, the year of entry into the study had the greatest impact.  Subjects entering 
the study within the years of 2002 and 2003 had 5 times better odds of being adherent 
compared to subjects entering within the years 1994 and 1995.  As subjects are more 
likely to have better adherence rates in the first year or two after diagnosis, the reason 
for this predictor may be that subjects entering in the latter part of the study period had 
less time to become non-adherent.  Another reason may be better acceptance of beta 
blocker use in heart failure patients by health care professionals and better adherence 
with guideline recommendations.   
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 Subjects filling a beta blocker within 1 month of index hospitalization had 1.5 
times better odds of being adherent compared to subjects filling a prescription after 
that time.  This may suggest that initiating life-saving drugs early on plays a big role 
on continued use of these medications and subsequent long term adherence.   
 Of interest is the fact that adherence to other medications, such as ACE 
inhibitors or ARBs, increased the likelihood of being adherent to a beta blocker by 
1.66 times.  Complexity of a patient’s drug regimen has been cited in the past as a 
reason for poor compliance, 82 but results from the Saskatchewan population may 
imply that polypharmacy does not necessarily have a negative impact on adherence.  A 
recent study supports this, as Gislason et al. found that multiple concomitant 
medication use was associated with the increased persistence of ACE inhibitors, 
ARBs, and beta blockers in heart failure patients. 92  
 
7.3 Phase III: Effects of Beta Blockers on Health Related Outcomes 
7.3.1 Effects of Beta Blocker Use on All-cause Mortality  
 Using a Cox proportional hazards model to analyze the effect of beta blocker 
use on all-cause mortality resulted in an unadjusted risk reduction of 33 percent.  This 
is similar to most of the landmark beta blocker trials in chronic systolic heart failure 
which showed an average risk reduction of approximately 35 percent. 52, 54, 56  After 
controlling for patient variables in our study, the risk reduction with beta blocker use 
was shown to be 61 percent which is similar to the 65 percent reduction in the risk of 
death seen in the US Carvedilol Heart Failure study. 55   
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 A Canadian trial examining the use of beta blockers in a heart failure clinic in 
Alberta, found that beta blocker use was associated with a 37 percent reduction in 
mortality risk after adjustment of patient characteristics. 119  Because the trial took 
place in a heart failure clinic, investigators had access to valuable information such as 
ejection fraction, type of heart failure, and NYHA class, all of which was included in 
their Cox proportional hazards model.  Although the adjusted risk reduction in this 
Canadian trial is not the same as that seen in the Saskatchewan population, both show 
a significant mortality benefit with the use of beta blockers within a real world 
population. 
 
7.3.2 The Effect of Beta Blocker Adherence on Health Related Outcomes  
 Patients demonstrating high adherence to beta blockers exhibited a higher 
chronic disease score and greater frequency of ischemic heart disease compared to 
non-adherent patients at baseline.  In contrast, the number of medical visits within the 
first six months is higher in the low adherence cohort.  A higher prevalence of ACE 
inhibitor, beta blocker and statin use was seen in the high adherence cohort, whereas 
digoxin was used more commonly in the low adherence groups.  The importance of all 
observed baseline differences was assessed and adjusted for in Cox proportional 
hazards models.    
 A survival advantage could not be demonstrated for subjects who exhibited 
high adherence compared to the low adherence group (HR = 1.18; p=0.07) in terms of 
all-cause mortality.  Interestingly, the small group of subjects categorized with 
medium adherence exhibited a statistically significant decrease in survival compared 
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to the low adherence cohort (HR = 1.41; p<0.01).  Secondary analysis examining the 
effect of beta blocker adherence on cardiovascular mortality and all-cause 
hospitalization shows similar results.  
 The reason for our inability to detect a survival advantage with increasing 
levels of adherence remains unclear.  All patients included within these survival 
analyses had a primary or most responsible diagnosis of heart failure, and for each 
patient there were 30 variables available from our database that could have been used 
in our Cox model.  All variables having a significant effect on survival time and all 
clinically relevant variables were used within each model.  Of course there is the 
possibility of missed information that was unavailable to us, such as lifestyle factors, 
smoking status and body mass index.  However, it is important to note that rates of 
obesity, smoking, and other such lifestyle risk factors would be expected to be lower in 
the adherent cohort due to the healthy adherer effect. 126   Overall, it is felt that the 
most important variables were included in the model and accounted for. 
 Selection bias is also an issue that needed to be examined.  In terms of the 
present study, selection bias refers to the unknown characteristics of a patient that may 
influence adherent behavior to a drug.  To both examine and limit selection bias in our 
data, a basic propensity analysis was performed for the primary endpoint of all-cause 
mortality.  Propensity analysis is a statistical tool that calculates the probability of a 
subject being assigned to a certain cohort based on known subject characteristics. 127  
Once the propensity score is calculated it can be used as part of a multivariate 
adjustment to account for possible selection bias. 127  Using the beta blocker adherence 
cohorts, a propensity score was calculated to predict the probability of a subject being 
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adherent based on each individual’s characteristics.  The scores were then categorized 
into quintiles and inserted into the Cox proportional hazards model.  No significant 
effects on survival time were noted, meaning that selection bias was not an issue 
within our analysis. 
 Certainly one limitation in our analysis would be the small sample size within 
each beta blocker cohort.  From a total of 1815 subjects in the adherence analysis, 
division resulted in a limited sample size of 1013, 270, and 532 subjects in the high, 
medium and low adherence cohorts, respectively.  Another limitation is the fact that no 
clinical evidence exists for the use of atenolol in heart failure.  As this drug has a high 
frequency of use in the heart failure population, and has similar properties to 
bisoprolol and metoprolol, it was included in our analysis.  Post-hoc subgroup 
analysis, which was conducted separately for carvedilol, metoprolol, and bisoprolol, 
resulted in no differences compared to patients taking atenolol.  Throughout this study 
we assumed that dispensations from community pharmacies were a direct measure of 
‘prescribing’.  As such, all prescribing rates were estimated solely on the basis of 
dispensing records.  Although there is a distinct difference between prescribing and 
dispensing, it is felt that this difference is likely to be small and it should be noted that 
other observational trials making use of administrative databases have made the same 
assumption. 76  Other limitations that have been stated previously, include our inability 
to distinguish between types of heart failure, and possible diagnostic issues. 
 In contrast to our study, Gislason et al. studied the effect of non-persistence 
with a beta blocker on survival time in Denmark and concluded that patients having a 
break in beta blocker therapy of at least 90 days have a higher risk of death than 
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patients without that break in therapy. 92  Interestingly, of all subjects who were 
classified as non-persistent, almost half of these patients re-initiated a beta blocker 
after the 90 day break in therapy.  The patient population within this study was very 
similar to that seen in our study, and the only major difference, aside from the 
adherence measure used, is that there were a total of 107,092 patients with a first 
hospitalization of heart failure, and 29,084 patients started on a beta blocker and were 
included in their survival analysis. 
 Another adherence paper in heart failure patients examined the effect of 
digoxin non-compliance on hospitalization and mortality. 105  Digoxin compliance was 
measured using serum drug concentration, and it was found that non-compliance to 
digoxin resulted in a 2.5 times higher rate of hospitalization and a two times higher 
mortality rate.  Although patients were suffering from chronic heart failure, digoxin 
was prescribed for treatment of supraventricular tachycardia.  As this medication has 
not been shown to reduce mortality in patients with heart failure128, the results seen 
may be due to the control of resting heart rate and not because of any beneficial effect 
on heart failure. 
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8. CONCLUSIONS 
 The data presented herein clearly demonstrates a vast underutilization of both 
beta blockers and ACE inhibitors or ARBs in heart failure patients.  Even in the 
patients receiving these life-saving medications, a large delay in obtaining the first 
prescription was observed for many.  Clearly, much work is needed by health care 
professionals to improve the management of heart failure patients in the community 
setting.   
 For those patients prescribed beta blockers and ACE inhibitors, it appears that 
adherence is generally optimal in the first year.  Unfortunately, over time, these 
medications are not filled on a regular basis or are being stopped altogether.  It needs 
to be realized by both patients and health care professionals just how important it is to 
continue taking these medications for the treatment of heart failure.  A most interesting 
finding, in regards to adherence, was that concomitant medication use increases the 
likelihood of adherence to a beta blocker. 
  Similar to the landmark beta blocker trials, we were able to show in this real-
world sample, that use of beta blockers was significantly associated with increased 
survival.  In contrast, we were unable to detect a mortality benefit due to optimal 
adherence.  However, the overall rate of adherence was excellent in the vast majority 
of patients during the first year.  It is possible that non-adherence is not responsible for 
a significant burden of mortality in Saskatchewan heart failure patients and the focus 
of quality improvement should be optimal prescribing of evidence-based therapies.      
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Identification of Exclusion Diagnoses Through Saskatchewan Health Databases 
HIV/AIDS 
 ICD-9:  
• 042 to 44.x, 795.8 
ICD-10:  
• B20 to B24.xxx, R75, Z21 
 
Medication use:  
• abacavir, amprenavir, delavirdine, didanosine, efavirenz, 
indinavir, lamivudine, lopinavir, nelfinavir, nevirapine, 
rotinavir, saquinavir, stavudine, zalcitabine, zidovudine 
Solid organ 
transplant  
 
ICD-9:  
• V42.0 to V42.8 inclusive 
ICD-10:  
• Z94.0 to Z94.4xx inclusive 
CCP:  
• 45.5x, 45.6x, 49.5x, 62.4x, 64.8x, 67.5x  
FFS:  
• 303R-305R, 307R, 308R, 350D 
Medication use:  
• cyclosporine, mycophenolate mofetil, sirolimus, tacrolimus
Terminal 
illness 
 
ICD-9:  
• V58.8 
ICD-10:  
• Z51.5 
 Medication use:  
• Any prescription fill with palliative care coverage 
 
ICD–9: World Health Organization International Classification of Diseases, Ninth 
Revision codes - diagnoses from hospital services database discharge abstracts 
ICD-10: World Health Organization International Classification of Diseases, Tenth 
Revision codes - diagnoses from hospital services database discharge abstracts 
CCP: Canadian Classification of Diagnostic, Therapeutic, and Surgical Procedures - 
codes for procedures performed during hospital stays in the hospital services database 
discharge abstracts 
FFS: Fee for service codes billed through the physician services database 
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1.  Sex – refers to the gender of the patient.  This information was given to us in 
the subject file database from Saskatchewan Health.  For analysis purposes, this was a 
dichotomous variable: male and female. 
 
2.  Age – refers to the age of the subject at the time of index hospitalization.  The 
date of birth is available from the subject file database, and age was calculated based 
on this information.  For analysis purposes, this was a continuous variable. 
 
3.  ACE inhibitor or ARB adherence – From the drug database, all fills for an ACE 
inhibitor and/or an ARB were selected for all patients.  From this information, 
adherence was calculated using the fill frequency measure of adherence (global 
perspective).  These values were adjusted based on hospitalization throughout the 
study period.  This continuous variable was then broken down into three categories for 
the purpose of analysis:  patients with adherence > 80 percent, patients with adherence 
< 80 percent, and patients not taking an ACE inhibitor or an ARB. 
 
4.  Anti-arrhythmic drug use – refers to whether or not a subject filled at least one 
prescription for a medication (with the exception of digoxin, beta blockers and calcium 
channel blockers) used in the treatment of arrhythmia.  An anti-arrhythmic drug was 
considered to be one of the following: mexiletine, procainamide, propafenone, 
disopyramide, flecainide, quinidine, amiodarone, tocainide or sotalol.  This 
information was acquired from the drug database, and anyone filling at least one 
prescription for an anti-arrhythmic agent within the study period was selected.  This 
variable was dichotomous in nature. 
 
5.  Digoxin use – refers to whether or not a subject filled at least one prescription 
of digoxin within the study period, and as such this was a dichotomous variable.  This 
information was obtained through the drug database. 
 
6.  Use of diabetes medications – refers to whether or not a subject filled at least 
one prescription for any type of diabetic medication (oral or injectable) within the 
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study period, and as such this was a dichotomous variable.  A diabetic medication was 
considered to be one of the following: acarbose, acetohexamide, chlorpropamide, 
glyburide, insulin, metformin, nateglinide, phenformin, pioglitazone, repaglinide, 
rosiglitazone or tolbutamide.  This information was obtained through the drug 
database. 
 
7.  Hydralazine use – refers to whether or not a subject filled at least one 
prescription of hydralazine within the study period, and as such this was a 
dichotomous variable.  This information was obtained through the drug database. 
 
8.  Loop diuretic use – refers to whether or not a subject filled at least one 
prescription of a loop diuretic within the study period, and as such this was a 
dichotomous variable.  A loop diuretic was considered to be one of the following: 
furosemide, bumetanide or ethacrynic acid.  This information was obtained through the 
drug database. 
 
9.  Physician caring for patient at index hospitalization – refers to the type of 
physician caring for the patient during their index hospitalization.  Type of physician 
includes general practitioner, internist, cardiologist or other.  This information is given 
to us in the hospital services database.  This variable is categorical in nature. 
 
10.  Non-dihydropyridine calcium channel blocker use – refers to whether or not a 
subject filled at least one prescription of a non-dihydropyridine calcium channel 
blocker (diltiazem or verapamil) within the study period, and as such this was a 
dichotomous variable.  This information was obtained through the drug database. 
 
11.  Nitrate use – refers to whether or not a subject filled at least one prescription 
of a nitrate within the study period, and as such this was a dichotomous variable.  A 
nitrate was considered to be one of the following: erythrityl tetranitrate, isosorbide 
dinitrate, isosorbide mononitrate or nitroglycerin.  This information was obtained 
through the drug database. 
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12.  Number of hospitalizations in the year prior to index – refers to the number of 
times a patient was admitted to hospital (excluding day surgery admissions) in the year 
prior to the index hospitalization.  This variable was calculated using the hospital 
services database, and was broken down into the following categories: 0 
hospitalizations, 1 to 2 hospitalizations, and > 3 hospitalizations. 
 
13.  Use of other hypertension medications – refers to whether or not a subject 
filled at least one prescription for a hypertension medication not already included in 
another variable.  The term other hypertension medication was considered to be one of 
the following: clonidine, doxazosin, guanethidine, methyldopa, minoxidil, nimodipine, 
prazosin, reserpine, terazosin, amlodipine, felodipine, nicardipine or nifedipine.  This 
information was obtained from the drug database, and the variable was dichotomous in 
nature. 
 
14.  Prior ACE inhibitor use – refers to whether or not a subject filled at least one 
prescription of an ACE inhibitor in the five years prior to the index hospitalization, and 
as such this was a dichotomous variable.  This information was obtained through the 
drug database. 
 
15.  Prior beta blocker use – refers to whether or not a subject filled at least one 
prescription of any beta blocker in the five years prior to the index hospitalization, and 
as such this was a dichotomous variable.  This information was obtained through the 
drug database. 
 
16.  Prior statin use – refers to whether or not a subject filled at least one 
prescription of a statin in the five years prior to the index hospitalization, and as such 
this was a dichotomous variable.  A statin was considered to be one of the following: 
atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin.  
This information was obtained through the drug database. 
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17.  Prior ischemic heart disease – refers to whether or not a subject had any 
evidence of prior ischemic heart disease in the five years prior to the index 
hospitalization, and as such this was a dichotomous variable.  Information for this 
variable was obtained from the hospital services database, and evidence of prior 
ischemic heart disease comes from either a diagnosis of myocardial infarction or other 
ischemic heart disease, or from a surgical admission for PTCA or CABG. 
 
18.  Drug benefits category at index – refers to the type of drug coverage benefits 
(if any) that a subject was receiving at the time of index hospitalization.  There are five 
categories: regular benefits, Saskatchewan assistance plan, family based income 
security programs, senior based programs, and the palliative care drug program.  The 
majority (95 percent) of patients either had regular coverage or were receiving benefits 
from the senior based program.  As there are five categories, this variable was 
categorical in nature.  Information for this variable was obtained from the drug 
database. 
 
19.  Renal failure – refers to any patient presenting with evidence of renal failure 
within the study period, and as such this was a dichotomous variable.  A diagnosis of 
renal failure or occurrence of renal dialysis was determined to be evidence of renal 
failure.  This information was taken from both the hospital services and the medical 
visits database.    
 
20.  Spironolactone use – refers to whether or not a subject filled at least one 
prescription of spironolactone within the study period, and as such this was a 
dichotomous variable.  This information was obtained through the drug database. 
 
21.  Statin use – refers to whether or not a subject filled at least one prescription of 
a statin within the study period, and as such this was a dichotomous variable.  A statin 
was considered to be one of the following: atorvastatin, cerivastatin, fluvastatin, 
lovastatin, pravastatin, rosuvastatin, simvastatin.  This information was obtained 
through the drug database. 
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22.  Thiazide diuretic use – refers to whether or not a subject filled at least one 
prescription of a thiazide diuretic within the study period, and as such this was a 
dichotomous variable.  A thiazide diuretic was considered to be one of the following: 
hydrochlorothiazide (HCTZ), metolazone, a combination of amiloride and HCTZ, and 
a combination of triamterene and HCTZ.  This information was obtained through the 
drug database. 
 
23.  Warfarin use – refers to whether or not a subject filled at least one prescription 
of warfarin within the study period, and as such this was a dichotomous variable.  This 
information was obtained through the drug database. 
 
24.  Year at index hospitalization – refers to the year that a subject had their index 
hospitalization.  This variable was broken down into two year periods and as such is a 
categorical variable as follows: 1994/95, 1996/97, 1998/99, 2000/01, 2002/03.  This 
information was taken from the subjects file database. 
 
25.  Days spent in hospital at index hospitalization – refers to the length of time a 
subject was in the hospital for at their index hospitalization.  This information was 
gathered from the hospital services data base and recorded in days.  Number of days 
was then broken down into the following five separate categories: up to 2 days, 3 to 5 
days, 6 to 11 days, 12 to 20 days, and > 20 days. 
 
26.  Deyo comorbidity score – is a score that reflects the overall health of a patient 
at baseline, and the higher the score a patient has, the less healthy they are.  This score 
was adapted and developed by Deyo et al. for use in administrative databases.113, 114  
The comorbidity score was calculated by Saskatchewan health based on ICD-9 and 
ICD-10 codes and given to us in the subject file database.  The comorbidity score was 
broken down into the following four separate categories: 0, 1, 2 and > 3. 
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27.  Chronic disease score – is a score that reflects the overall health of a patient at 
baseline, and the higher the score a patient has, the less healthy they are.  This score is 
created using the number of distinct drug classes being dispensed in the year prior to 
the index hospitalization.  The calculation for this score is based on a paper by Von 
Korff et al.112  Saskatchewan Health calculated the chronic disease score for each 
patient and included it in the subject file database.  The score was broken down into 
the following 5 separate categories: 0 to 3, 4 to 5, 6 to 7, 8 to 9, and > 10. 
 
28.  Number of diseases at index – refers to the number of disease states that each 
patient had at the time of index hospitalization.  This information was taken from the 
subjects file database and was calculated based on medication use for various disease 
states that was given to us from the chronic disease score calculation.  This variable 
was broken down into the following five separate categories: 0, 1, 2, 3, 4, and > 5. 
 
29.  Number of physician visits within the first six months after index – refers to 
the number of outpatient physician visits each subject had in the first six months after 
index hospitalization.  The information for this variable was taken from the medical 
visits database.  This variable was broken down into the following five separate 
categories: 0 to 10, 11 to 16, 17 to 23, 24 to 33, and > 34. 
 
30.  Number of hospitalizations in the first six months after index – refers to the 
number of times a subject was hospitalized in the first six months after index 
hospitalization.  The information for this variable was taken from the hospital services 
database.  This variable was broken down into the following 4 separate categories: 0, 
1, 2, and > 3. 
 
 
 
 
 
